Metabolic effects of growth hormone by Hoos, M.B.
  
 
Metabolic effects of growth hormone
Citation for published version (APA):
Hoos, M. B. (2003). Metabolic effects of growth hormone. Maastricht: Universiteit Maastricht.
Document status and date:
Published: 01/01/2003
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
ni ihrim
IIUUIIII
VLAG
The study presented in this thesis is a research project of the department of pediatrics of
the University hospital Maastricht and the University Maastricht and was performed at the
Nutrition and Toxicology Research Institute Maastricht (NUTRIM) which participates in the
Graduate School VLAG (Food technology, Agrobiotechnology, Nutrition and Health
Sciences), accredited by the Royal Netherlands Academy of Arts and Sciences.
Product/on ^ ^ '
Andi Drukwerkindustrie Geleen * 4.
Cover
fotografre: Hugo Thomassen
Mode/: Sem Cuypers
© Maria Benedikte Hoos, Maastricht 2003
ISBN 90-9017014-6
METABOLIC EFFECTS
OF GROWTH HORMONE
Proefschrift
ter verkrijging van de graad van doctor
aan de Universiteit Maastricht,
op gezag van de Rector Magnificus,
Prof. dr. A.C. Nieuwenhuijzen Kruseman
volgens het besluit van het College van Decanen
in het openbaar te verdedigen
op donderdag 3 juli 2003 om 16.00 uur
door
Maria Benedikte Hoos
Geboren te Moordrecht op 21 december 1973
Promotores •
Prof. dr. R.A.M.G. Donckerwolcke
Prof. dr. K.R. Westerterp
Co-promotor
Dr. W.J.M. Gerver
Beoordelingscommissie
Prof. dr. C.E. Blanco
Prof. dr. H.A. Delemarre-van de Waal (Vrije Universiteit Amsterdam)
Prof. dr. S.L.S. Drop (Erasmus Universiteit Rotterdam)
Prof. dr. H. Kuipers
Dr. N.C. Schaper
Answers Thal Maller.
The studies described in this thesis were financially supported by Eli Lilly, the Netherlands.
Financial support by the Dr. ir. van de Laar Stichting, Ferring B.V. and Nutricia Nederland
B.V. for the publication of this thesis is gratefully acknowledged.
CONTENTS
CHAPTER 1
Introduction 3
CHAPTER 2
Physical activity levels in children and adolescents 33
CHAPTER 3
Physical activity level measured by doubly
labeled water and accelerometry in children 45
CHAPTER 4
Physical activity pattern of children assessed
by tri-axial accelerometry 53
CHAPTER 5
Physical activity in children receiving growth hormone
therapy as measured by tri-axial accelerometry 67
CHAPTER 6
Endurance time and grip strength in children ^
receiving growth hormone therapy . 77
CHAPTER 7
Short-term effects of growth hormone on
body composition as a predictor of growth 85
CHAPTER 8
Discussion 97
Summary 705
Samenvatting 707
Dankwoord 777
Curriculum vitae 773
List of publications 7 75

CHAPTER 1
INTRODUCTION
GENERAL INTRODUCTION 5
GROWTH AND GROWTH HORMONE 6
Normal growth 6
Regulation of growth hormone secretion 7
Regulation of growth by the pituitary: the somatomedin hypothesis S
DIAGNOSING GROWTH HORMONE DEFICIENCY 9
Growth hormone secretion in the diagnosis of growth hormone deficiency 9
Evaluation of the arginine stimulation test at the department
of Pediatrics University Maastricht 70
Prediction of the effect of GH therapy on growth 73
METABOLIC PREDICTORS FOR THE EFFECT
OF GROWTH HORMONE ON GROWTH 74
Physical activity 74
Effects of growth hormone on energy expenditure
and physical activity related energy expenditure 76
Body composition 77
Effects of growth hormone on body composition and physical fitness 78
OUTLINE OF THE THESIS 79
Chapter 1
Introduction
GENERAL INTRODUCTION
Human growth follows a narrow, genetically defined path. Any deviation on its way to
adolescence must be regarded as a consequence of any interference with the child's general
health. It is therefore important to watch a child's growth pattern. Although there are many
well-known circumstances with a negative effect on growth, the underlying
pathophysiology remains largely unknown. Even more elusive are the mechanisms that
result in catch-up growth after repair of the failure.
The main hormonal cause of growth retardation, insufficient growth hormone (GH)
secretion, was treated for the first time in 1958 (1). Because the GH administered was
extracted from human cadavers, its supply was limited and only patients with proven severe
growth hormone deficiency (GHD) had access to this treatment. The diagnostic criteria
used were severe retarded growth and serum peak GH concentrations after stimulation not
exceeding 9 mU/l. Problems arose in 1984, when a 20-year-old man, who had started GH
treatment before the age of 3 years, died of Creutzfeldt-Jakob disease (2) 17 years later.
Creutzfeldt-Jakob disease is a degenerative neurological disease, which is transmissible by
contact with abnormal prions that are located within the central nervous system of affected
subjects. Because Creutzfeldt-Jakob disease is an unusual disease in a patient aged 20, it
did not take long before the link between contamination by the supplied pituitary GH and
Creutzfeldt-Jakob disease was made. After the discovery of another two cases, treatments
with human GH were stopped on April 19, 1985 (2).
Several months later, the already developed technique to produce growth hormone by
means of recombinant DNA was approved by the Food and Drug Administration (FDA).
Because the supply of GH was now (technically) unlimited, therapy was no longer restricted
to severely growth hormone deficient children. Partially growth hormone deficient patients,
who did not meet the earlier strict criteria, also became eligible for treatment and often
showed a positive, though unpredictable, response to therapy. This unpredictability has led
to extensive discussions. There is ongoing debate about the value of endocrine testing, in
which GH concentrations are measured in serum, as a method to distinguish GH deficient
children from those whose stunted growth is based on other factors. Nevertheless, these
endocrine tests are still being applied, because other methods to predict the effect of
therapy are almost not available.
The incentive to start the present study was to find out if short-term metabolic changes
induced by growth hormone therapy would be able to predict the long-term effect of
growth hormone on growth. The study was focused on two effects of GH on metabolism.
First, it is a common experience among doctors and parents that growth hormone deficient
children become livelier and more active after the introduction of GH therapy. Secondly,
there is increasing evidence in the literature about the changes in body composition caused
byGH.
Both of these metabolic effects, which appear after a brief period of GH treatment, might
be used as predictors for the long-term growth effect.
GROWTH AND GROWTH HORMONE
Normal growth
Evaluating a child's growth requires reference data for children matched for age, race and
sex. Several sets of reference data are available for the Dutch population (3-6).
A standard growth chart can be derived from a data set in two steps. First, the 50* centile
is constructed by drawing a smooth curve, usually by a least squares approximation,
through the whole data set. Subsequently, the age specific standard distributions must be
estimated by dividing the population into age groups and calculating the mean and
standard deviation (SD) for each of them. A smoothed line connects the obtained SD values
and represents the standard deviation for the whole population. This approach requires the
population to be normally distributed. In the case of a skewed distribution, several methods
can be applied, the most common of which is a transformation of the data set into a
symmetric Gaussian distribution. Gerver and de Bruin applied a method in which the
population is divided into a group above and a group below the 50* centile (5). Assuming
these groups to be normally distributed, they calculated the standard deviation for each
group.
Instead of standard deviations, percentiles can be used. Percentiles simply rank the
members of the population by height, thus reflecting the height distribution within the
population. They are not hampered by a skewed distribution. A height that equals P,Q (the
10* percentile) implies that the child belongs to the 10% smallest children in that
population. The calculation of percentiles can be used to obtain the values of P^j, PJQ and
P „ from moderate sample sizes. Estimation of the third and 97* percentiles, however,
requires extremely large sample sizes. Therefore, percentiles are often derived from the
standard deviations, where +2 SDS equals the 97.7* centile, and -2 SDS the 2.3* centile.
It must be realized that percentiles derived from SDS have lost their original meaning.
When evaluating a child's growth, three items have to be taken into consideration: height,
height velocity and the target height. The child's height is evaluated relative to that of the
reference population. The height measurement is plotted on the growth chart or expressed
as standard deviation score (SDS):
SDS, = (x, - (j,)/o,
where x, denotes height score at aget, u, the population mean at age, and o, the SD of the
reference population at age t. A SDS outside 2 SDS is considered to be beyond the normal
range. Secondly, besides the actual height of a child, one needs to be informed about its
growth. At least two measurements are necessary to calculate the height velocity. In
children beyond the age of one year, an interval of at least three months is necessary for
an accurate interpretation of their growth. A difference in height velocity of more than 0.25
SDS in one year is regarded as outside the normal range.
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The target height is an approximation of the child's expected height as an adult, in view of
its genetic potential. The target height is calculated by taking the height of the father
(reduced for girls by the male-female difference in the adult population) and that of the
mother (increased for boys by the male-female difference in the adult population) divided
by two, plus an increment correcting for the secular trend. The target height can also be
calculated in terms of SDS as: height SDS of the father + height SDS of the mother, divided
by two. When comparing the target height with the child's actual height, a difference of
more than 1.3 SDS (or 8.5 cm) for Dutch children is regarded as abnormal. In this case, the
child's height does not correspond to its genetic potential (7). The growth chart shows
whether a child's growth is within the normal range. If growth is found to be outside the
normal range, diagnostics have to be applied.
Regulation of growth hormone secretion
The growth-promoting substance from the pituitary gland was first isolated in cows as
bovine growth hormone in 1944 (8, 9), and afterwards in humans as human CH, around
1956 (10,11). Growth hormone is a single-chain polypeptide consisting of 191 amino acids
and secreted by somatotrophic cells in the anterior pituitary. Some 70-75% of the growth
hormone circulates in the blood as a 22 kDa molecule, while the second largest fraction of
the circulating GH pool consists of a 20 kDA form (12). Several mechanisms cause the
heterogeneity of GH in serum. Chromosome 17 includes two GH genes, termed hGH-N
(for normal) and hGH-V (for variant). The two corresponding proteins are highly
homologous and differ by 13 of the 191 amino acids. The hGH-N gene is expressed in the
pituitary gland, the hGH-V gene primarily in the placenta (13, 14). Transcripts of the hGH-
N gene are spliced into two different mRNAs, creating the 20 kDa and 22 kDa forms (15).
Additional variation is caused at the post-translational level by modifications of monomeric
forms, as well as oligomerization. The binding of GH to binding proteins (GHBP) in the
circulation creates extra complexity. Finally, metabolic products such as proteolytic
fragments of GH contribute to the variety of GH forms (16).
The secretion of GH by the anterior pituitary is pulsatile and controlled by two
neurohormones, which are produced by the hypothalamus and continually influence the
secretory rate of GH. GH secretion is stimulated by the GH releasing hormone (GHRH) (17,
18). In contrast, somatostatin, also called GH inhibiting hormone (GHIH), inhibits GH
secretion (19). Pulses of GH secretion occur at times of maximum GHRH and minimum
GHIH secretion (20, 21). Tonic GHIH secretion is important for maintaining low basal GH
levels.
In addition to GHRH and GHIH, GH release is also influenced by free fatty acids, leptin,
neuropeptide-Y and ghrelin (22, 23). Free fatty acids act directly on the pituitary to inhibit
GH release. Because GH stimulates lipid mobilization, this is hypothesized to constitute a
feedback loop (24, 25). Leptin stimulates GH release from the hypothalamus by regulating
GHRH and GHIH activity (26-28). The effect of leptin may also involve neuropeptide-Y
(NPY), since leptin suppresses NPY expression and infusion of NPY is known to suppress
CH secretion (29, 30). Ghrelin appears to be a more potent inducer of GH release than
GHRH and exhibits a synergistic effect with GHRH (31, 32). It is predominantly produced
by the stomach (33-35) but has also been found in lower amounts in the intestine (33),
pituitary (36), kidney (37), placenta (38) and hypothalamus (35). GH itself also acts on the
hypothalamus to affect its own secretion.
Insulin-like growth factor-l (IGF-I or somatomedin), a mediator of the effects of GH on
tissues, influences the secretion of GH by binding to specific receptors in the pituitary and
suppressing GH gene transcription and GH secretion (39, 40). IGF-I circulates in the blood
either as a free molecule (t,^ is about 15-20 minutes) or bound to specific high affinity
binding proteins that prolong the half-life of the peptide (41, 42) by protecting it from
proteolytic degradation. So far, six IGF-I binding proteins (IGFBPs) have been identified.
The circulating IGFBPs act as carrier proteins and regulate the availability of IGF-I at its
receptor in target tissues (43). Specific proteases are necessary to cleave IGF-I from its
binding protein complex (41). The major circulating form of IGF-I is a high molecular
weight complex consisting of IGF, IGFBP-3 and ALS (acid-labile subunit) (44). The release
of IGF from this large complex leads to the formation of smaller complexes with other
IGFBPs, which are believed to transport IGFs out of the circulation. Most target tissues
express IGFBPs that regulate the local action of IGFs.
GH also circulates in plasma attached to a specific, low capacity binding protein (GHBP)
(45-47), which is homologous to the cleaved extracellular domain of the GH receptor (48,
49). GH binds with high affinity to its receptor, which is found in tissues throughout the
body. The molecule exhibits two binding sites for the GH receptor, causing dimerization of
the receptor. This step is required for biological activity of the hormone (50).
Regulation of growth by the pituitary: the somatomedin hypothesis
The somatomedin hypothesis explains the regulation of somatic growth by the pituitary.
According to the original somatomedin hypothesis (1950s), GH was thought to stimulate
IGF-I synthesis and release from the liver. IGF-I was believed to reach the main target
organs such as cartilage and bones via the circulation and to act as an endocrine agent.
Circulating IGF-I was also thought to have a feedback effect, because it was supposed to
suppress the further release of GH from the pituitary (51).
This hypothesis was first challenged by the discovery of local IGF-I and IGF-II production in
most, if not all tissues. This strongly suggested an autocrine/paracrine effect of IGF-I (52-
54). According to the alternative somatomedin hypothesis, both circulating and locally
produced IGF-I are responsible for the effects of GH. In addition, the possibility that GH
may have IGF-I independent effects on tissues could not be excluded (22, 23).
In 1985, Green et al (55) proposed the 'dual effector theory' to explain the roles of GH and
IGF-I in growth and differentiation. This theory suggests that GH stimulates the
differentiation of adipocytes and that IGF-I stimulates further expansion (55). Isaksson
extended the dual effector theory to the growth plate, by proposing that GH acts directly
at the germinal zone to stimulate the differentiation of chondrocytes. Furthermore, GH
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enhances the local production of ICF-I, which in turn stimulates the expansion of
chondrocytes in an autocrine/paracrine manner (56, 57).
Gene targeting technologies in rodents have provided further insight into the GH-IGF axis.
IGF-I proved to have prenatal as well as postnatal significance, in contrast to IGF-II, which
is only important during prenatal stages (58). Isaksson (59) et al. showed that inactivation
of liver-produced IGF-I results in increased serum levels of insulin, leptin and cholesterol, a
state of insulin resistance and eventually a decrease in fat mass. These findings show that
endocrine IGF-I is not required for post-natal growth, but is important for the regulation of
carbohydrate and lipid metabolism (59, 60). In contrast, the autocrine/paracrine IGF-I
production is sufficient for normal growth and development, although a direct effect of GH
on non-hepatic tissues cannot be excluded (60).
DIAGNOSING GROWTH HORMONE DEFICIENCY
Growth hormone secretion in the diagnosis of growth hormone deficiency
The Dutch Growth Foundation (Nederlands Groeistichting, NGS) regulates the prescription
of GH therapy in the Netherlands. Before approval to start GH therapy is given, the
following criteria have to be met (61, 62):
• exclusion of other causes of growth retardation than GH deficiency;
• height below-2.5 SDS;
• a decrease in height of more than 0.25 SDS over at least one year;
• retarded skeletal maturation (> 1 SD);
• decreased or below-normal IGF-I levels;
• maximum GH concentration in two endocrine provocation tests not exceeding
20mU/l.
Although several problems arise in the use of endocrine tests to estimate insufficient growth
hormone secretion, the outcome of such tests is still the essential (if not the only) element
in the decision to start GH therapy (63).
Pituitary secretion of GH from somatotrophic cells is pulsatile, with the most consistent
peaks occurring during phases 3 and 4 of sleep (64). Between these pulses, GH
concentration may drop to very low levels. This is the reason why random blood samples
give very little information about a child's GH secretory status. The best indication of
growth hormone secretion status is obtained from the pattern of GH release during 24-
hour sampling, but this is hardly feasible.
Hence, a child's GH production is usually evaluated by means of provocation tests.
However, there are several reasons why the value of endocrine tests for evaluating GH
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secretion is still a subject of debate (63, 65-69). First of all, any stimulation by drugs does
not represent the normal secretory dynamics (70). Secondly, there are important differences
in the way the various stimulating drugs influence GH concentration. Clonidine, for
example, induces GH release via central a-adrenergic effects, while arginine increases GH
secretion by inhibition of GHIH release.
Thirdly, and even more importantly, there are differences in the measurements of GH
concentrations in serum, which relate to the existence of several forms of GH in the blood.
Different assays may recognize GH isoforms to varying degrees, making results of different
assays and laboratories hard to compare (16).
Last but not least, other factors influencing GH secretion, like stress, age, puberty, obesity
and emotional deprivation, may also affect the diagnosis (70).
There exists international agreement that peak GH concentrations, whether spontaneous
or by provocation, exceed 20 mU/l in normally growing children. At the same time, the
above arguments, as well as the knowledge that endocrine tests are used differently (63)
by different centres and that different laboratories make use of different assays, mean that
it is virtually impossible to define a general cut-off value to distinguish normal from
abnormal GH production.
To settle at least one point of debate, a harmonization factor has been introduced in the
Netherlands to rectify the differences in the measurement of GH concentrations in serum.
In 2001 the Section Endocrinology (LWBA=landelijke werkgroep bindingsanalyse) of the
Dutch Foundation for Quality Assessment in Clinical Laboratories (SKZL=Stichting
Kwaliteitsbewaking Ziekenhuis Laboratoria) initiated the harmonization of the growth
hormone assays in the Netherlands.
Each laboratory has received a harmonization sample with an attributed GH concentration.
This sample has been proven to be commutable for all used assays in the Netherlands,
which means that there is no interference between sample and method. The measured
value is used to establish a harmonization factor in laboratories, which makes the measured
concentration equal to the attributed concentration. Pediatricians are obliged to report only
harmonized GH concentrations when submitting test results to the Dutch Growth
Foundation. This makes measured GH concentrations comparable within all pediatric
centers of the Netherlands. Since 2003, all laboratories in the Netherlands are obliged by
the LWBA to use the harmonization factor.
Evaluation of the arginine stimulation test at the department of Pediatrics
University hospital Maastricht
To enforce the basic assumption of the present thesis of endocrine tests being ineffective
for the prediction of the effect of GH on growth, the use of the arginine test was evaluated
in 26 children previously treated with GH at the department of Pediatrics, University
Hospital Maastricht. Growth retardation was defined on the basis of one of the following
anthropometric criteria:
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• height below -2.5 SDS;
• change in height SDS of more than -0.25 SDS in one year;
• height below -1.3 SDS of the target height (7).
If other reasons than those related to GH for growth retardation were present, children
were excluded.
All children had undergone an arginine growth hormone stimulation test because of
suspected growth retardation based on one of the above anthropometric criteria. Change
in height SDS after one year of therapy was taken as effect parameter. A mean change of
0.7 SDS during the first year of therapy was considered to be a good reaction on GH
therapy, being the mean value found in the international KIGS study (71).
The decision to start growth hormone therapy was not based on the result of the arginine
test only. Some of the patients had entered therapy despite a growth hormone response
exceeding 20 mU/l, because they met selection criteria based on anthropometric data.
Figure 1a shows the change in height SDS over 1 year against the maximum GH
concentration found during the arginine tests. Assuming two borderlines: a maximum GH
concentration found during the arginine test of 20 mU/l on the x-axis and a change in
height SDS after one year of therapy of 0.7 SDS on the y-axis, four quadrants are visible in
the chart. The arginine test would be a very good predictor for the effect of GH therapy if
Figure 1a
A/lax/mum growth hormone concentration found dur/ng (he arg/n/ne tesf by growfh /n the
f/rsf /ear of fherapy. 7he reference //nes /nd/'cate a change /n he/ghf of 0.7 SDS and a
growth hormone concentration of 20 ml///.
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all children were positioned in the upper left quadrant (good growth response and low CH
concentrations) or the lower right quadrant (poor growth response and high GH
concentrations). However, only 15 out of 26 children (57%) are situated in these two
quadrants.
Figure 1b shows the relation between the change in height SDS after one year of therapy
and the height before therapy, on the x-axis a borderline of -2.5 SDS is indicated. For this
parameter 18 out of 26 children (69%) were situated in the upper left and lower right
quadrant. According to this data, the arginine test is no better predictor for the growth
effect of GH therapy than the height SDS before the start of therapy.
At present, many countries require two endocrine tests showing low GH levels before a
patient becomes eligible for GH treatment. When comparing the maximum GH
concentration found during an arginine test to those values obtained after provocation with
clonidine in the same patients, it appeared that the diagnosis depends heavily on the test
which has been performed. Figure 1c shows the maximum GH concentrations found during
both tests. The indication of the GH concentration of 20 mU/l divides the figure into four
compartments. If both tests agreed, all children should have been situated in the lower left
or upper right quadrant. However, only 45% of the patients were located in these
quadrants. Also this example confirms the problems related to the use of endocrine tests as
described above and the need for another approach.
Figure 1b
He/ghf af start of therapy p/otted aga/nst growth /n the f/>si year of therapy. The reference
//nes /nc//cate a change /n he/ght of 0.7 SDS and a he/ghf of -2.5 SDS.
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Figure 1c
A/lax/mum CH concentration o/ tne c7on/c//ne test re/ated to tne max/mum concentration
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Prediction of the effect of GH therapy on growth
While in severe GHD, GH therapy may be expected to be effective in terms of growth
response, the outcome of the therapy in partial GHD is hard to predict. Growth prediction
models combine a selection of diagnostic variables to predict the longitudinal growth
response of a child to GH therapy. Models can be based on pre-treatment variables, early
effect variables, or both. The efficacy of a prediction model depends on its sensitivity and
specificity. If the most important aim is to detect patients who will not respond to
treatment, the model needs to have a high specificity, since specificity indicates the
proportion of patients who are predicted to be non-responding and do indeed not respond.
In contrast, a test with a high sensitivity correctly detects a high proportion of responders.
Most models presented in literature are based on baseline variables (71-78), although
models based on effect parameters have also been described (73, 79-83). The number of
parameters included ranges from 1 (80) to 6 (71). Such parameters include age (bone age
or chronological age), anthropometric parameters (height SDS before treatment, target
height SDS), outcome of endocrine tests and bone markers (alkaline phosphatase). Effect
parameter models often include the height velocity or the change in height during the first
3 months of therapy. The correlation coefficient of the models with the height velocity
ranges from 0.20 to 0.61. An exception is the recently described "Cologne model" (79).
This model is based on pretreatment bone age retardation as a fraction of chronological
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age, pretreatment serum levels of IGF-I, urinary levels of deoxypyridinoline (a bone
resorption marker) after 1 month of treatment and height velocity after 3 months of
treatment. The regression equation of this model explains 89% of the first-year growth
variation.
METABOLIC PREDICTORS FOR THE EFFECT OF GROWTH
HORMONE ON GROWTH
Physical activity
Physical activity and physical fitness are important for health. Inactivity increases the risk of
diseases, like coronary artery disease (84) hypertension (85) and diabetes mellitus (86).
Physical inactivity in childhood has been found to continue into adulthood (87), so the
promotion of regular physical activity in children could serve as a preventive health strategy.
Bringing about changes in habitual lifestyles, however, requires an understanding of the
current levels and patterns of physical activity. Physical activity is an important determinant
of the total daily energy expenditure (TDEE), which can be divided into four components:
• basal metabolic rate (BMR);
• diet induced thermogenesis (DIT);
• energy cost for growth;
• activity related energy expenditure (AEE).
BMR is the energy needed to maintain all vital body functions. This component can be
divided into sleeping metabolic rate (SMR) and the energy costs of waking up (arousal).
The second component of total daily energy expenditure is diet-induced thermogenesis,
the energy expenditure associated with the digestion of food. This constitutes about 10%
ot energy intake and thus contributes 10% to TDEE when intake matches energy
expenditure (88).
The energy needed to build up new tissues and the energy stored in the tissues are the
energy costs for growth. The final component, AEE, is the most variable component,
ranging from 25 to 35% of TDEE (88).
The 'gold standard' to measure TDEE is the doubly labeled water method, a method which
makes use of the stable isotopes ^H and ^ O . After oral ingestion, both isotopes dilute in
the body fluids. The hydrogen isotope is eliminated from the body as water, while the
oxygen isotope is eliminated as both water and carbon dioxide. The difference between the
two elimination rates is therefore a measure of carbon dioxide production (figure 1d).
Energy expenditure is calculated from measured COj production with Weir's equation:
EE (kcal)= 3.941 * VO-, (I) + 1.106 * VCO^ (I) (89)
Chapter 1
Introduction
15
Figure 1d
Pr/nc/p/e unc/er///V7g the doub/y /abe/ed wafer method. ^H and '*O are adm/n/sfered to
enhance natura/ enr/cbments of the /'sofopes above background /eve/s. The d/fference
between d/sappearance rates of ^H and '*O approximates the carbon d/ox/de output, wh/ch
/s then used to ca/cu/ate energy expend/fure (Adapted from He//man and Roberts (706.),).
output
H^O + COj output
isotopic background
T
dose
Time (days)
Where oxygen consumption is based on an estimated or measured value of the respiratory
quotient (RQ =
BMR can be measured using an open-circuit, ventilated hood system. It is measured in the
morning after an overnight fast, to avoid DIT being included in the measurement. The
subjects are asked to lie in supine position for 30 minutes. Oxygen consumption and carbon
dioxide production are calculated using the flow through the hood and the oxygen and
carbon dioxide concentrations in the incoming and outgoing air. B/WR is then calculated
using Weir's equation (89). Once TDEE and BMR are known, activity related energy
expenditure and physical activity level (PAL) can be calculated.
PAL is a measure introduced by the FAO/WHO/UNU expert committee on energy
requirements (90). This committee has expressed energy needs as multiples of the BMR,
which is called PAL (91). PAL can be calculated as TDEE/BMR, AEE = (0.9 * TDEE) - BMR,
assuming a DIT of 10%.
Using the doubly labeled water method, physical activity can be measured over a period of
one to two weeks under free-living conditions, without influencing the natural activity
behavior. However, since doubly labeled water is expensive and scarce, this method is not
suitable for population-based studies. Neither can it be used to measure physical activity
patterns.
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Other methods to measure physical activity related energy expenditure are self-report
instruments, personal observation, heart rate monitoring and accelerometers. Personal
observation is suitable for small sample sizes when information on a specific type of activity
and its duration is required. However, this method is time consuming and expensive, and
interferes with children's spontaneous activity patterns (92).
Self-report instruments have proved to correlate only moderately with objective activity
measures (93), because children are not able to provide accurate information about their
activity patterns. Although heart rate (HR) monitors give more objective information about
physical activity, it has been proven in adults (94-96) as well as in children (97, 98) that HR
monitoring overestimates 24-hour energy expenditure by about 10%, because factors like
emotional stress and posture can contribute to an increase in HR during inactive periods.
A more promising method for the measurement of physical activity related energy
expenditure is the use of motion sensors and more specifically, accelerometers. These
devices measure the occurrence and intensity of movements. There exist one-axial
accelerometers like Caltrac and CSA (Computer Science and Application's activity monitor)
and tri-axial accelerometers like Tritrac and Tracmor. Compared to the DLW method, the
Caltrac was not found to be accurate by Johnson et al. (99). Ekelund et al. (100) found a
good correlation between the CSA accelerometer and DLW data. Unlike Ekelund et al.,
Johnson converted accelerometer output to kcal/day on the basis of an equation including
age, height, weight and gender. Leenders et al. (101) observed significant underestimation
of physical activity by the CSA and Tritrac in women. In their study, the output of both-
meters was converted to energy expenditure parameters using subject characteristics.
The Tracmor has been developed at the department of Human Biology at the University of
Maastricht. It has proved to be an objective and reliable tool for assessing activity levels in
free-living subjects (102). In contrast to other accelerometers, Tracmor was miniaturized to
a small and light device (11 cm' and 30 g, Tracmor2), which is important for the subject's
comfort (103).
The importance of measuring physical activity patterns has become clear when the
Tracmor2 was used to assess physical activity patterns in adults (104). It showed that the
fraction of time spent on activities of moderate and low intensity is a significant predictor
of PAL, indicating that spending less time on low intensity activities positively influences
physical activity levels, whereas high intensity activities do not have much influence on the
physical activity level. This suggests that an increase in physical activity levels does not
necessarily imply high-intensity sports (104, 105).
Effects of growth hormone on energy expenditure and physical activity related
energy expenditure
Treating GHD adults with GH has been found to cause an increase in BMR (107-109).
Measuring the change in the BMR/fat free mass ratio (FFM) is not the best method to
investigate whether this increase can be entirely attributed to an increase in FFM. Ravussin
and Bogardus (110) warned against the use of this method, because the y-intercept is
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significantly greater than zero in a regression of BMR against FFM. Expressing data as the
BMR/FFM ratio will therefore always result in a higher BMR/FFM in those subjects with a
lower FFM. As CHD adults generally have a lower FFM than healthy controls, BMR/FFM
will be higher even though their BMR may lie within the normal regression line.
After adjusting for FFM as suggested by Ravussin and Bogardus, Snel et al. (109) found a
significant increase in BMR. This suggests that other factors besides the change in FFM also
influence the increase in BMR. The higher FFM adjusted BMR may be due to changes in
fuel metabolism. According to Snel, an increase in gluconeogenesis may be responsible for
the higher BMR. Juul and Salomon (111, 112) attributed most of the increase in metabolic
rate to the fat oxidation resulting from the lipolytic effect of growth hormone.
Also after the introduction of GH therapy in GHD children, changes in energy expenditure
occur (21, 113). Gregory for example, showed a significant increase in BMR (by 12 %) after
6 weeks of growth hormone treatment (113). The termination of GH treatment when the
final height is reached can also affect energy expenditure (114). Cowan demonstrated that
BMR was reduced within two weeks after growth hormone treatment was stopped, and
remained suppressed for up to one year later in individuals previously identified as having
childhood onset GHD (115).
Little is known about the effect of growth hormone therapy on activity related energy
expenditure. Although parents have reported their children to be livelier and more active
after the start of therapy, Gregory could not confirm this using the DLW method Because
growth hormone treatment causes an increase in fat free mass, an effect on physical activity
related energy expenditure might be expected. In the study by Gregory, however, the
increase in TDEE was a reflection of the increase in BMR, suggesting that growth hormone
treatment has no evident effect on activity related energy expenditure.
Body composition
Although weight is commonly used to estimate nutritional status, weight as an isolated
measurement provides little information. Since body weight is the sum of five principal
compartments: water, fat, protein, minerals and glycogen, changes in body weight may be
the result of changes in any of these compartments. Because the various body
compartments are difficult to measure separately, Siri divided the body into two
compartments: fat mass (FM) and fat free mass (FFM) (116). Most studies of body
composition are based on this two-compartment model.
Knowledge of the fat content of the body has physiological and medical importance. The
amount of fat may influence morbidity and mortality, it may alter the effectiveness of drugs
and anesthetics and it may affect the ability to withstand exposure to cold and starvation
(117). Besides fat mass, water content also reflects the nutritional status of the body. Moore
suggested that most illnesses result in increased hydration of the body. He postulated that
in disease, as pathologic water accumulation develops, the hydration of the fat free mass
may rise from 73% to 84% (118, 119), indicating that the measurement of body fat and
body water provides useful information (117).
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The current density standard is based on three studies in which human male cadavers were
analyzed to get more information about the density of fat and fat free mass. (120-122).
This analysis was used to define the current density standard of 0.9007 g/ml for fat and
1.10 g/ml for fat free mass at average body temperature (36 °C) (116, 123). However, it
has long been known that young tissues differ from old ones in chemical composition (122,
124, 125). The young body has a higher proportion of water and a lower proportion of
minerals; young bones contain less calcium, young muscle less potassium. In addition, the
ratio of extracellular water (ECW) to intracellular water (ICW) declines during growth
(126). Therefore, the current density standards for fat mass and fat free mass are not
applicable to children.
Effects of growth hormone on body composition and physical fitness
The lipolytic effect of GH was demonstrated in the 1930s, when studies showed that the
injection of rats with extracts from the anterior pituitary gland reduced body fat.
Subsequent studies using purified GH preparations demonstrated that this effect was
caused by GH (127). The most important pathway for accumulating triglycerides in human
adipose tissue is the lipoprotein lipase (LPL) pathway. LPL hydrolyzes triglycerides that are
transported as VLDL-triglycerides and chylomicrones. Several hormones, like insulin and
corticosteroids, regulate the activity of LPL (128). Ottosson et al. showed that GH inhibits
lipoprotein lipase activity in human adipose tissue (129). In addition to the effect on fat
mass, nitrogen retention increases within days of starting GH treatment. Increased nitrogen
retention reflects increased protein synthesis and fat free mass (115).
Because GH has effects on the body's fat mass and fat free mass, abnormalities in body
composition are to be expected in GHD patients. A few studies have presented data of
body mass index (BMI) in children with retarded growth. Leger (130) found a BMI of -0.2
kg/m^ at the start of therapy for GHD children. Children with intrauterine growth
retardation were found to have a BMI of -1.3 kg/W. Baars et al. (131) found a BMI-SDS
of 0.09 before GH treatment, which was comparable to that in normal children. During
therapy, BMI initially decreased, to reach a nadir of -0.28 SDS at 6 months. Thereafter, BMI
progressively increased to -0.09 SDS after 24 months.
The effects of GH on fat mass and fat free mass have been investigated in adult patients (18,
111) as well as in children (21,113, 132-136). The initiation of therapy causes a decrease in
fat mass and an increase in fat free mass in GH deficient patients. By contrast, children who
terminate their GH treatment because they have reached their final height have been found
to show an increase in fat mass and a decrease in fat free mass (114, 115, 137).
The treatment of adult patients with GH initially results in oedema. However, with the
recognition that adults with GHD require significantly smaller doses of GH than children,
the frequency and severity of the problems have been greatly reduced (138). Vaisman et
al. found no effect on extracellular water (ECW) in children who were treated with GH
(135). Parra (136) showed ECW for age to be lower in GHD children before the start of
therapy, although ECW for height was normal.
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The effect of GH on body composition has been found to be transient, (113,130,132,133,
135,139). Vaisman (21) observed that fat as a percentage of body weight decreased within
2 months and was unchanged at 4 and 6 months of treatment. Hindmarsh, who examined
triceps and subscapular skinfolds, reported a significant decrease after 6 months and a
return to baseline at 12 months (140).
Besides the changes in fat mass and fat free mass in GHD patients, changes in fat
distribution have been described. The distribution of body fat in GHD adults is
characteristically altered; there is an increase in the abdominal and visceral depots, resulting
in an increase in the waist-to-hip ratio compared with controls (141,142). Studies (18,143)
have shown that the reduction in fat mass during GH therapy is region-specific, with the
greatest reduction occurring centrally and smaller changes occurring in the limbs. These
findings confirm the observations by Salomon et al. (111), who showed that GH reduces
the waist-to-hip ratio. Thus, GH promotes a redistribution of adipose tissue from abdominal
to peripheral depots. Matsuoka postulated that these regional differences might suggest
that GH has site-selective lipolytic activity. The redistribution of body fat may be due to the
effect of interactions with other hormones, whose activity may be different at different sites
(144).
Apart from effects on body composition, effects on cardiac function have also become clear
in GHD adults. (145-147). They were found to have impaired cardiac function (148, 149),
which improves after the introduction of GH therapy (148, 150-153). In addition to
improved cardiac function, increased exercise tolerance (154-158) and muscle strength
have been reported, which might improve physical fitness and the ability to perform
everyday tasks. (155, 159-161).
OUTLINE OF THE THESIS
It is beyond doubt that it is difficult to diagnose GHD. The present study was designed
because current methods have proved to be inadequate in predicting the effect of therapy.
The aim of the study was to evaluate whether changes in physical activity or body
composition shortly after the start of therapy could predict the effect of GH therapy on
long-term growth.
Before deviant physical activity patterns could be identified in children who benefit from
GH therapy, more knowledge was needed about physical activity in healthy, normally
growing children. Therefore, Chapter 2 shows the results of a literature study, analysing
existing studies that had measured total daily energy expenditure with doubly labeled
water, in order to evaluate the effect of age on activity. Chapter 3 describes a validation
study with the Tracmor2 accelerometer for the measurement of physical activity in children.
This instrument was used in the study reported on in Chapter 4 to evaluate the activity
pattern of children compared to that of young adults and the elderly.
Because GH affects energy expenditure and body composition, it was expected that
children secreting less GH would be less physical active and show poorer physical fitness.
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The studies reported on in Chapters 5 and 6 compared the effect of GH therapy on activity
patterns and physical fitness in children receiving GH therapy with those of healthy
controls.
It is known that it is difficult to select children who will benefit from GH therapy. Because
previous research has found a relation between the change in height resulting from GH
therapy and changes in body composition (114, 139), chapter 7 proposes a new method
based on metabolic changes caused by GH therapy, to select children that will respond to
the therapy. This chapter describes the use of changes in body composition after the
introduction of GH therapy as a predictor of the long-term growth effect. Body
composition was measured before and after only 6 weeks of GH therapy, because it is
important that the decision to continue or stop therapy can be made soon after its start.
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ABSTRACT
Background
Reference data for physical activity level (PAL) and activity related energy expenditure
(AEE) are needed for a better understanding of the effect of activity on childhood health,
growth and development
Objective
Data from 17 studies measuring total daily energy expenditure (TDEE) with doubly labeled
water, were combined to construct a reference line for PAL and AEE as a function of age.
Design
A total of 17 studies from the literature were analyzed; 17 on girls and 16 on boys. Children
were aged 3-16 years and of Caucasian origin. Weighted least squares regression was used
to obtain reference lines for PAL and AEE as a function of age and gender. The relative
numbers of children per study were used as a weighting factor. Basal metabolic rate (BMR)
or non-fasted resting metabolic rate and sex were included in the analysis.
Results
Although there was no difference in PAL between boys and girls, a significant difference in
AEE was found between the two sexes.
PAL 0.025 * age + 1.40
AEE (MJ/d) boys: 0.30 * age + 0.025; girls: 0.21 * age + 0.33
If BMR is measured under non-fasted conditions, the obtained value has to be reduced by
0.21 for PAL and 0.75 MJ/d for AEE. No relation was found between AEE/kg and age.
Conclusions
PAL and AEE were found to increase with age, showing the importance of age-dependent
recommendations. Recommendations for AEE need to be differentiated for sex. To compare
PAL and AEE between studies, the measurement conditions of BMR have to be taken into
account. The increase in PAL and AEE values can be attributed to an increase in weight,
because there was no relation between AEE/kg and age.
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INTRODUCTION
Industrialized countries are seeing an increase in the prevalence of childhood obesity, which
is strongly associated with obesity in adulthood (1, 2). This increase in obesity is probably
caused by recent changes in life-style. Not only have there been quantitative and
qualitative dietary changes, but children now spend a large part of their free leisure time
watching television or playing computer games (3). While in adults the health benefits of
physical activity have been well established (4), it is more difficult to determine the
beneficial effect of activity on health in children, since it takes many years before any effect
can be observed.
As physical activity determines a large proportion of a person's energy requirements, new
recommendations for dietary intake and physical activity might be necessary to prevent
obesity. A better understanding of the effect of physical activity on childhood obesity could
be obtained from information on the average activity level of the current childhood
population.
The amount of physical activity can be expressed as the physical activity level (PAL) or as
the activity-related energy expenditure (AEE). The basis for PAL was formulated in 1985 by
the FAO/WHO/UNU expert committee on energy requirements (5). This committee
expressed the energy needs as multiples of the BMR (basal metabolic rate). The index TDEE
(total daily energy expenditure) over BMR (TDEE/BMR) was referred to as the PAL (6).
TDEE and BMR can subsequently be used to calculate the activity-related energy
expenditure: AEE = (0.9 * TDEE) - BMR, assuming a diet induced thermogenesis (DIT) of
10%.
In 1995, energy requirements were reconsidered by the International Dietary Exchange
Consultancy group (IDECG) (7). Instead of using energy intake data of healthy thriving
children, which used to be the basic assumption in the previous reference data, this group
used energy expenditure data based on the doubly labeled water (DLW) method, heart rate
monitoring and activity diaries. The panel also recommended energy requirements based
on PAL.
Normal levels for PAL are the subject of ongoing debate in adults and also in children. The
recommendations, which use PAL values to calculate total daily energy expenditure show
little differentiation for ages, which makes it impossible to calculate the expected PAL or
AEE value at a certain age.
The DLW method is currently regarded as the gold standard for measuring energy
expenditure (8), as it is reasonably easy to use and a valuable method, based on stable
isotopes. Since, the isotopes are expensive, most studies have included small numbers of
subjects. The present paper analyzes combined data from 17 studies from literature with
the aim of constructing a reference line for PAL and AEE as a function of age. Separate lines
were constructed for boys and girls to investigate the effect of sex.
METHODS
All studies from the literature that included TDEE measurement by DLW among children
aged 3-16 were potentially eligible for inclusion in the present review. The studies were
found by a computerized search for relevant articles on MEDLINE (Pubmed) using the
following terms: double labeled water, DLW and TDEE with the limit: all children: 0-18
years. In addition the references of the found articles were screened.
The ethnicity of the subjects was predominantly Caucasian. Only in two studies (9, 10),
containing 82 and 78% of Caucasian children, the distinction between ethnic groups could
not be made.
All studies distinguished between data for boys and girls. Intervention studies were
excluded, or only their basal values were used. Studies on obese and undernourished
children were excluded. Table 2a and 2b describe the mean percentage (and range) of fat
mass or the body mass index (BMI) (if no data on fat mass were available) of the study
populations. Studies with subject groups outside these ranges were not evaluated.
Studies indicating that resting metabolic rate was measured after the consumption of
breakfast were marked as non-fasted (NF) in table 2a (for boys) and table 2b (for girls).
Other studies, including studies with predicted metabolic rate, were marked as fasted (F).
The regularly applied protocol, where the thermic effect of food was included, was the
consumption of a usual breakfast at home before the children came to the laboratory
(9, 11).
Two studies (12, 13) calculated BMR values, using Schofield's formula (14), while the other
studies measured BMR values using a ventilated hood system. The measuring period of the
DLW method was within the optimal range of 7-14 days (15). PAL was calculated as
TDEE/BMR, while AEE was calculated as (0.9 * TDEE)-BMR, assuming a DIT of 10%.
STATISTICS
To compensate for the differences in the number of children per study, a weighted least
squares linear regression was performed between age and PAL, age and AEE, and between
age and AEE/kg for both sexes, using the relative number of children per study as the
weighting factor. To test the difference between boys and girls, an interaction term
(age*sex) was included in the analysis. Since some studies measured non fasted metabolic
rate instead of BMR, a parameter named feeding (BMR= 0, non fasted metabolic rate = 1)
was included in the analysis.
RESULTS
The energy expenditure parameters used in each study are listed in table 2a for boys and
in table 2b for girls. In all, 16 studies were included for boys and 17 for girls.
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Table 2a Energy expend/ture parameters per study for boys.
Author
Atkin et al<">
Bandini et al<">
Bandini et al<">
Black et al"®
Bratteby et al<^»
Ekelund et al<">
Fontvieille et al^'
Goran et aP"'
Goran«"'
Goran et al<*>>
Hoffman et al<"°>
Johnson et al ' ""
Livingstone et al'^^'
Luke et al<**>
Nguyen et al<"
Sun et al<*">
n
39
13
2
29
32
31
25
15
15
5
8
3
25
11
11
11
14
17
6
5
5
3
5
36
21
Age
(years)
3.1
14.4
16.2
4.7
9.8
14.5
15.0
9.1
5.4
4.0
5.0
6.0
5.3
5.3
6.4
9.3
10.2
8.2
7.5
9.3
12.3
15.4
8.4
5.2
8.3
BMR
(MJ/d)
3.45
7.26
7.42
3.80
3.12
8.10
7.31
5.21
4.34
4.48
4.78
5.06
4.57
4.91
5.29
5.91
5.21
5.54
4.72
4.75
6.30
6.70
5.40
4.50
5.20
TDEE
(MJ/d)
5.12
13.00
12.84
6.10
9.80
14.10
13.82
8.87
5.92
5.64
6.26
6.02
5.78
6.59
7.54
8.67
9.03
8.04
7.98
9.77
10.69
11.00
8.83
6.40
7.12
AEE
(MJ/d)
1.15
4.44
4.14
1.69
3.12
4.59
5.13
2.78
0.98
0.59
0.85
0.35
0.63
1.02
1.50
1.89
2.92
1.70
2.46
4.04
3.32
3.18
2.55
1.26
1.21
PAL
1.48
1.79
1.73
1.61
1.72
1.74
1.89
1.70
1.36
1.26
1.31
1.19
1.27
1.34
1.42
1.47
1.73
1.45
1.69
2.05
1.70
1.64
1.64
1.42
1.37
BMR
F/NF
F
F
F
F
F
F
F
F
F
NF
NF
NF
NF
NF
NF
NF
F
NF
F
F
F
F
F
NF
F
% fat mass
(±sd)
23(6)
16(5)
17(3)
16(2)»
20 (4)"
25 (9) *
16(6)
20(6)
22(4)
17(5)
19(4)
20(2)
19(4)
13(4)
16(5)
22(7)
17(6)
25(7)
18(4)
19(4)
24(5)
14(5)
25(12)
14b
24"
BA/lfi, basa/ mefabo//c rate; 7D£E, tota/ da/7y energy expend/ture; A££, act/V/fy re/ated
energy expend/ture, PA/., pnys/ca/ act/wty /eve/, f=ß/Wß, /Vf= Won fast/ng metabo//c rate.
*ß/W/ are g/Ven because no data on fat mass were ava/7ab/e. *Wo standard dev/at/on (sdj
was ava/7ab/e because % fat mass was ca/cu/ated from we/ght and fat mass.
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The weighted least squares linear regression yielded the following regression equation for
PAL:
PAL = 0.025 * age+1.40
(r= 0.85, p<0.001, standard error = 0.10)
If the non-fasted metabolic rate is measured, the obtained value should be reduced by
0.21, because feeding was a significant (p< 0.0001) variable in the regression model. The
inclusion of age and age'sex in the analysis was not significant (F change =1.62, p =0.21).
For AEE, there was a significant difference between boys and girls (F change 12.5, p<
0.0001). Therefore equations are given for boys and girls separately:
Boys: AEE = 0.30 * age + 0.025 ; Girls: AEE = 0.21 * age + 0.33
(r= 0.94, p<0.001, standard error = 0.44)
Also in this model feeding was a significant contributor. So if the non-fasted metabolic rate
is measured, AEE has to be reduced with 0.75 (MJ/d). AEE/kg was not significantly related
to age for boys nor for girls.
DISCUSSION
For all kinds of research questions, energy expenditure of children is measured. Several
studies use the DLW method, which is regarded as the 'gold standard'. The results of these
studies are used in the present paper to estimate the relation between physical activity and
age represented by the construction of a reference line.
Reference data for PAL and AEE are needed for a better understanding of the activity level
of children, which is especially relevant in childhood obesity. Several studies have
demonstrated a negative relation between body fat and physical activity (16-19) or activity
time (20). Some studies showed a sex difference in the relation of physical activity and body
fat (21-23). All these studies show the importance of physical activity in the treatment of
obesity, which can be evaluated if normal values of a healthy population are available.
Although children may appear to be more active than adults, the present review actually
found low values in young children increasing to adult values with age. This might be
explained from the observation made by Noland et al. (24) who showed that the energy
cost of playing is less than that of a slow walk. Besides, children's activities are not only low
in intensity but also not sustained over extended periods of time (25). Although children
need more energy per kilogram body weight to perform a particular activity than adults
(26), their lower body weight leads to a smaller overall energy expenditure compared to
older subjects.
In addition to the effect of body weight, there is a pronounced difference between children
and adults in the time they are active. Adults showed to have a mean sleeping time of
8 hours (27, 28). In a recent study we found a mean sleeping time of 11 hours in children
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Table 2b fnergy expend/ture parameters per study for g/r/s.
Author n Age BMR TDEE AEE PAL BMR % fat mass
(years) (MJ/d) (MJ/d) (MJ/d) F/NF (± sd)
Atkinetal '") 38 3.1 3.19 4.85 1.17 1.52 F 25(6)
Bandini et al<"> 10 14.1 5.98 10.12 3.13 1.69 F 25(7)
Bandini et al«5> 2 14.4 6.51 12.28 4.55 1.89 F 33(2)
Black et al<"> 21 4.9 3.60 5.50 1.35 1.53 F 15(1)«
24 9.2 4.80 8.00 2.40 1.67 F 18(2)»
26 14.8 6.70 11.40 3.56 1.70 F 27(9)»
Bratteby et al<^> 25 15.0 5.97 10.70 3.66 1.79 F 28(6)
Craig et al"°> 49 10.1 5.35 8.37 2.18 1.56 F 21(6)
Ekelund et al<"> 11 9.1 5.14 8.25 2.29 1.61 F 27(6)
Fontvieille et al"> 13 5.5 4.01 5.63 1.06 1.41 F 23(5)
Goran et al«» 4 4.0 4.14 4.39 -0.19 1.06 NF 19(4)
4 5.0 4.63 5.69 0.49 1.23 NF 26(4)
6 6.0 4.75 6.05 0.69 1.27 NF 26(7)
Goran<"> 26 5.1 4.24 5.24 0.48 1.24 NF 26(7)
Goran et al<"> 11 5.5 4.57 5.71 0.57 1.25 NF 19(5)
11 6.6 4.79 7.59 2.05 1.59 NF 20(6)
11 9.5 5.44 6.72 0.61 1.24 NF 27(6)
Hoffman et al<*°> 15 10.0 4.66 8.08 2.61 1.73 F 24(6)
Johnson et al<^> 14 8.5 5.19 6.50 0.65 1.25 NF 26(7)
Livingstone et al<«> 5 7.4 4.36 7.14 2.07 1.64 F 21(2)
4 9.2 4.43 8.14 2.89 1.84 F 27(3)
5 12.4 5.85 9.89 3.05 1.69 F 28(3)
3 15.6 5.14 9.57 3.48 1.86 F 27(9)
Luke et al<«> 4 6.8 4.47 6.74 1.59 1.51 F 35(9)
Nguyen et a P 35 5.5 4.30 5.90 1.01 1.37 NF 18^
Sunetal<^> 18 8.4 5.35 8.14 1.97 1.52 F 39^
R, basa/ metabo//c rate; TDff, tofa/ da/7y energy expend/ture; A££, arf/V/ty re/ated
energy expend/ture; PA/., pnys/ca/ act/V/ty /eve/. F=S/VI/?, Wf= A/on fast/ng mefafco//c rate.
*ß/W/ are g/Ven because no data on fat mass were ava//ab/e .*Wo standard dewaf/on (sd)
was ava/7ab/e because % fat mass was ca/cu/ated from we/gnt and fat mass.
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with a mean age of 8.6 years (personal observation). As children grow older, they sleep less
and spend more time on physical activities, resulting in higher PAL and AEE values.
The present review found no difference in PAL values between boys and girls, but did show
a difference between the sexes in AEE. Boys had higher AEE values than girls, which might
be explained by the difference in body composition between the two. Body composition
does not influence PAL, because this parameter adjusts energy expenditure for BMR, which
depends heavily on body composition.
PAL and AEE describe the amount of energy spent on activity. However energy costs of
physical activity do not need to be identical to body movement (29). Schoeller and Jefford
(30) suggested normalizing the energy expenditure of physical activity by division by body
weight. No relation was found between AEE/kg and age, which means that the increase in
PAL and AEE can be contributed to the increase in weight.
Longitudinal studies describing the participation into different activity levels (31-33),
measured by interviews and questionnaires, reported a decline in physical activity with age
especially after the age of 12-15 years. The time spent on activities decreases, but because
there is an increase in weight the total amount of energy spent on physical activity might
increase.
PAL was defined by the WHO in 1985 as TDEE/BMR. However sometimes non fasted
metabolic rate, which includes the thermic effect of food, was measured. In the present
analysis we corrected for this and showed that for the comparison of PAL and AEE data,
one has to take the measurement conditions of BMR in mind.
Because of the high cost of the DLW method, the studies tended to include relatively small
numbers of children. Our analysis would have yielded more precise results if ages and
energy expenditure data had been available for individual subjects. The ratio of the means
may differ from the mean of the individual ratios. As it was, we had to use aggregated data,
which could have attenuated the relation. Moreover, we cannot exclude the possibility that
another factor, related to age and influencing TDEE, could be (at least partly) responsible
for the observed relations.
In conclusion, PAL and AEE values increased with age. The increase can be attributed to an
increase in body weight.
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ABSTRACT
The present study investigated the use of a tri-axial accelerometer, Tracmor2, for the
measurement of physical activity in children. Eleven children (age 6.9 (±2.2) years, body
weight 19.5 (±5.3) kg and height 112.3 (±14.4) cm) were studied. Total daily energy
expenditure (TDEE) was measured by the doubly labeled water method over a two weeks
period. In addition, basal metabolic rate (BMR) was determined by the ventilated hood
system. Physical activity level (PAL) was defined as TDEE/BMR. Tracmor2 was worn during
the identical two weeks period throughout waking hours after which average counts/day
were calculated. The average counts/day showed to be highly correlated to PAL values
measured by doubly labeled water: PAL= 1.156 10^ * counts/day + 0.978 (r=0.79, p
<0.01). In conclusion, Tracmor2 is a valid instrument to measure physical activity in children
under free-living conditions.
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INTRODUCTION
Physical activity and physical fitness are important for health and development. Inactivity
increases the risk of diseases associated with our modern lifestyle. Because physical
inactivity in childhood has been found to continue into adulthood, the promotion of regular
physical activity in children could serve as a preventive health strategy. Bringing about
changes in habitual lifestyles requires an understanding of the current levels and patterns
of physical activity.
The doubly labeled water (DLW) method is regarded as the 'gold standard' for the
measurement of physical activity. It estimates physical activity under free-living conditions
over a period of 1 -2 weeks. However, labeled water is expensive, not easily available and
cannot be used for the measurement of physical activity patterns. Accelerometers,
validated against DLW, are a good alternative for the measurement of physical activity
patterns.
Accelerometers register the occurrence and intensity of body movement. Two classes of
accelerometers are described in literature: uni-axial and tri-axial accelerometers. Johnson
et al. (1) validated the Caltrac device, which measures accelerations in one direction.
Compared to the DLW method the Caltrac was not found to be accurate. Ekelund et al. (2)
used a CSA activity monitor, which is also a uni-axial accelerometer, and found a good
correlation between the accelerometer and DLW data. In contrast, Leenders et al. showed
an underestimation of physical activity expressed as kcal/day measured by the CSA (3) and
the Tritrac, a tri-axial accelerometer. Another tri-axial accelerometer, the Tracmor did prove
to be a reliable tool for assessing physical activity in adults (4).
The present study validates the Tracmor2 in children. The Tracmor2 is, in contrast to the
Tracmor used by Bouten et al. a much smaller and lighter device, which minimizes subject's
discomfort.
SUBJECTS AND METHODS
Subjects and study design
Eleven children in the age range of 3-12 years were selected. The children were healthy and
free from any medical condition that could restrict their physical activity. The children visited
the hospital early in the morning for basal metabolic rate (BMR) measurements. From that
moment, the Tracmor2 was worn for a period of two weeks. The evening preceding the
BMR measurement the children received a dose of ^ H ^ O . During the two-weeks period,
urine samples were collected and stored at -20 °C until ^H and ^ O enrichments were
measured. Parents and children were informed about the study before informed consent
was obtained. The study was approved by the Ethical Committee of the University Hospital
Maastricht.
Doubly labeled water and ventilated hood
Estimating physical activity by DLW requires information about total daily energy
expenditure (TDEE) and BMR. Total daily energy expenditure was measured by the doubly
labeled water method according to the Maastricht protocol (5). A weighed dose of water
with a measured enrichment of about 5 atom % ^H and 10 atom %^O was ingested in
the evening preceding the BMR measurement. This dose results in an initial excess body
water enrichment of 150 ppm for ^H and 300 ppm for ^O. A baseline urine sample was
collected before dosing. Additional urine samples were collected in the mornings and
evenings of days 1, 8 and 15. Samples were analyzed on an isotope-ratio mass
spectrometer (Optima; VG Isogas, Middlewich Cheshire, England).
The hydrogen isotope is eliminated from the body as water, while the oxygen isotope is
eliminated as both water and carbon dioxide. The difference between the two elimination
rates is therefore a measure of carbon dioxide production. Total daily energy expenditure
was calculated, using Weir's equations (6), from carbon dioxide production assuming a
respiratory quotient (RQ) of 0.85.
BMR was measured using an open-circuit, ventilated hood system in the morning after an
overnight fast. The subjects were asked to lie in supine position for 30 minutes. Gas
analyses were made with a paramagnetic oxygen analyzer (Servomex type 500A,
Crowborough Sussex, UK) and with an infrared carbon dioxide analyzer (Servomex type
500A), similar to the system described by Schoffelen et al. (7). Oxygen consumption and
carbon dioxide production were calculated using the flow through the hood and the
oxygen and carbon dioxide concentrations in the incoming and outgoing air. Weir's
equations were used to calculate BMR (6). Knowing TDEE and BMR, physical activity level
(PAL) can be calculated as: TDEE/BMR.
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Accelerometer
The Tracmor2 (Tracmor2, Philips Research, Eindhoven, The Netherlands), a tri-axial
accelerometer, was worn for 2 weeks. The Tracmor2 is a small (7 x 2.8 x 0.8 cm) and light
(30 g) device, which is worn attached to an elastic belt at the back of the waist. The tri-
axial accelerometer calculates the sum of the rectified and integrated acceleration curves
from the anteroposterior, mediolateral and vertical directions of the trunk. The integration
period was set at 1 min and the final output is expressed as counts per minute (c.p.m.) (4).
The Tracmor2 was worn during waking hours, except while showering and during
swimming. The parents of the children recorded the moments when the children woke up,
put the Tracmor2 on and off and went to bed. If the time during which they wore the
device and the time spent sleeping did not add up to at least 22 hours, the day was
excluded from the analysis (mean number of recorded days 11). Average daily counts were
calculated.
STATISTICS
A linear regression analysis was performed for the PAL (TDEE/BMR) measured with the
DLW method and the Tracmor2 (average counts/day) output.
RESULTS
Subject characteristics are given in table 3a. The mean age of the children was 6.9 (±2.2)
years, body weight was 19.5 (±5.3) kg and height was 112.3 (±14.4) cm. Linear regression
analysis resulted in the following equation for the calculation of PAL values (figure 3a):
PAL= 1.156 10-5 . Tracmor2 average counts/day. + 0.978 (r=0.79, p <0.01)
DISCUSSION
As our awareness of the effect of inactivity on health and development increases, so does
the interest in methods to measure physical activity. Because physical inactivity in children
continues into adulthood, prevention of inactivity is especially in this age group of great
importance. When measuring physical activity, one has to be sure that the measurement
does not interfere with the child's daily activities. Accelerometers are therefore a good
alternative for the DLW method, which is considered to be the 'gold standard'.
The present study showed the Tracmor2 to be a valuable instrument for the evaluation of
physical activity in children. Bouten et al. (4) compared activity counts from the Tracmor
with energy expenditure in adult subjects. A correlation coefficient of 0.58 (p<0.001) was
found. The correlation improved to a value comparable to those of the present study (0.73)
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Table 3a Su£>/ert character/stars.
Subject
No.
1
2
3
4
5
6
7
8
9
10
11
Age
(years)
5.9
6.8
5.8
11.1
6.6
3.4
8.3
5.9
4.9
9.8
7.1
Sex
(M/F)
F
F
F
M
F
F
F
F
M
M
F
Height
(cm)
100.3
103.8
95.9
130.9
103.7
97.4
129.3
115.0
101.7
128.8
128.6
Weight
(kg)
18.0
15.0
12.3
25.2
14.8
15.4
27.5
19.7
16.7
23.5
26.4
kCounts/
day
30.7
34.3
39.9
60.8
34.1
39.2
31.0
53.8
48.3
53.4
58.7
TDEE
(MJ)
5.06
5.45
5.07
8.29
4.64
5.26
6.57
5.60
6.25
7.27
7.57
BMR
(MJ)
3.69
4.40
3.49
4.54
3.43
3.56
4.58
4.03
4.00
4.47
4.64
TDff: Iota/ da/7y energy expend/fure; ß/W/?: basa/ mefabo/ic rate; /W: ma/e; F: fema/e.
when counts were corrected for counts that were the results of vibrations produced by
transportation. Because these vibrations are in Tracmor2 removed by a low-pass filter, this
correction is not necessary when using Tracmor2.
Two other studies in children describe the validation of an accelerometer. Johnson et al. did
not find a relation between Caltrac and DLW data. Ekelund et al. found a correlation of
0.54 (2) between average activity counts and physical activity measured by DLW using the
CSA. Another study in women by Leenders et al. did not find a relation between CSA and
DLW data (3). Like Johnson et al., that study converted accelerometer output to kcal/day
on the basis of an equation including age, height, weight and gender.
Besides the CSA the study showed the Tritrac, a tri-axial accelerometer, to underestimate
physical activity. Also Tritrac output was converted to kcal/day with use of equations based
on weight, height, sex and age. This means that the measurement of physical activity
depends in addition to accelerometer output on subject characteristics.
The lower correlation found by Ekelund et al. compared to the present study can probably
be contributed to the fact that Ekelund used the CSA accelerometer, which is a uni-axial
accelerometer. This device only registers movements in the vertical plane in contrast to the
Tracmor, which measures movements in three directions.
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Figure 3a •
P/7/s/ca/ acf/V/ty /eve/s (PA/.= Iota/ da/7y energy expend/ture/basa/ metabo//c
measured by tfie doub/y /abe/ec/ water fecrin/cjue p/otted aga/nst fne average da/7y
Tracmor counts. Trie so//d //ne represents trie regress/on //ne; P/\L= 7.756 70"* *
counts/day + 0.978 (r=0.79, p <0.07j.
20 30 40 50 60 70
Tracmor2 (average counts/day)
The position of attachment to the body can also influence accelerometer output. Ideally,
several accelerometers are used, attached to different sites to the body, however this is very
unpleasant for the subject. Therefore the Tracmor, CSA and Tritrac are attached to the
waist, which is close to the center of gravity. The Caltrac was not attached to the waist, but
to the hip.
When measuring physical activity it is important not to disturb the regular pattern of
physical activity. Therefore it is important to minimize subject's discomfort. The Tracmor2 is
worn around the waist attached to an elastic belt. Because the Tracmor2 is a small device
it can be covered invisible with clothing. In addition, the Tracmor2 is a light device
compared to other accelerometers.
We conclude that because the Tracmor2 can be used under free-living conditions, does not
interfere with the child's habitual activity pattern and showed to be highly correlated to the
DLW method, it may be considered as the most appropriate device for the assessment of
physical activity in children.
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Objectives
Accelerometry was used to assess the relationship between physical activity level (PAL) and
time spent on activities of various intensities in children.
Methods
Twenty children aged 8.6 ± 3.3 years wore a tri-axial accelerometer (Tracmor2) for two
weeks. PAL was calculated with Tracmor2 output data. The fraction of time spent on
activities with a given level of intensity (low, moderate, high) was calculated. The fractions
of time spent on activities of different intensities were compared with previously obtained
data for young adults and elderly persons.
Results
PAL showed an inverse relation with the percentage of time spent on low-intensity activities
(r= 0.76; p<0.0001) and a positive relation with the percentage of time spent on high-
intensity activities (r=0.93; p< 0.0001). The fraction of time spent on low-intensity activities
was smaller in children than in young adults (p<0.05) and elderly persons (p<0.0001), while
the fraction spent on high-intensity activities (p<0.0001) was larger.
Conclusions
Our observations suggest that to obtain a higher PAL in children, children should be given
the opportunities to perform high-intensity activities. In addition, children should be
educated about the importance of regular physical activity to prevent inactivity in
adulthood.
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INTRODUCTION
Physical inactivity becomes more and more a characteristic of our modern way of life. At
the same time, obesity becomes an increasing problem among adults and even among
children (1). Because it still remains unclear how much of the increase in obesity is
attributable to an inactive lifestyle, there is a growing interest in the measurement of
physical activity.
In the Netherlands, ten percent of the children between ages 5 and 11 are obese (2) and
obesity in childhood is predictable for obesity at adult age (3-5). Therefore the prevention
of physical inactivity should begin in early life. However bringing about changes in the
habitual lifestyle of children requires an understanding of their current levels and patterns
of activity.
Physical activity can be assessed in different ways. With use of the doubly labeled water
(DLW) method, physical activity can be measured over a 1-2 weeks period, without
interfering with the subject's natural activity behavior (6). The technique is easy applicable
and implies for the subject only the collection of some urine samples. The DLW method is
regarded as the 'gold standard' for the validation of other instruments measuring physical
activity. However a practical limitation of large-scale application of the DLW technique is
the high costs. In addition, the DLW method can only be used to measure the average
physical activity level. Accelerometers on the other hand are able to measure physical
activity intensity and physical activity patterns, i.e. the time spent on activities of low
(sitting), moderate (walking) and high-intensity (running) activities. The CSA (Computer
Science and Applications Inc. monitor) and Tracmor have been validated against DLW and
proven to be reliable tools for the assessment of physical activity (7, 8). The CSA is a uni-
axial accelerometer. Uni-axial accelerometers measure the occurrence and intensity of
movements in the horizontal plane (8). The Tracmor, a tri-axial accelerometer, registers
movements in three dimensions (7).
The Tracmor has been used to measure physical activity patterns in adults (7, 9). These
studies showed that spending more time on moderate-intensity activities and thereby
reducing the time spent on low-intensity activities, is more effective in increasing overall
activity levels than spending more time on high intensity activities. This is most likely
explained by the fact that high-intensity activities are usually performed for a short period
of time.
In children less is known about physical activity patterns. Although it is generally assumed
that children are more active than adults, no studies exist comparing physical activity
patterns of children to those of adults. The present study was aimed at the measurement
of levels and patterns of physical activity in healthy children, using an accelerometer.
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RESULTS
The fraction of time spent on low and high intensity activities was significantly correlated to
PAL (r= 0.76; p<0.0001 and r= 0.93; p< 0.0001, respectively), whereas the fraction of time
spent on moderate intensity activities was not significantly correlated to PAL (figure 4a).
Children spend 56% of their time on low-intensity activities, 25% on moderate intensity
activities and 19% on high intensity activities. This activity pattern was compared to
previously published activity patterns of adults (7) and the elderly (10). The fraction of time
spent on low intensity activities was significantly lower in children than in adults (p<0.05)
and elderly persons (p< 0.0001), while the fraction of time spent on high intensity activities
was significantly higher in children than in adults and elderly persons (p<0.0001) (table 4a).
The fraction of time spent on moderate intensity activities was significantly higher in the
children than in the elderly (p <0.0001), though it did not differ significantly from that in
adults (figure 4b).
DISCUSSION
Because of the negative effects that physical inactivity may have on health, the interest in
methods to measure physical activity levels increases. Although an increasing number of
health promotion programs aim to change activity patterns, few data are available about
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DISCUSSION
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Table 4a Da/7y amount o^ s/eep and art/V/fy f/me, pnys/ca/ act/Vrty /eve/ (PAU and
percentage of f;me spent on act/wt;es of tow, moderate, and h/gh /ntens/ty. Data for young
adu/fc and e/de/7y persons obta/ned from prewous stud/es (7, 70,).
Variable (unit)
Sleeping time (h/d)
Activity time (h/d)
PAL
Low activity (%)
Moderate activity (%)
High activity (%)
children
mean
11.2
12.3
1.5
56
25
19
range
9.4-12.2
11.1-14.7
1.3-1.9
41-73
16-39
9-31
adults
mean
8.3
13.7
1.77
65
25
9
range
6.7-10.5
10.9-16.1
1.5-2.0
52-82
11-36
3-15
elderly
mean
8.5
14.4
1.65
82
15
4
range
6.4-11.5
11.7-17.2
1.4-2.0
66-95
3-22
1-12
the physical activity pattern and of the factors that affect the physical activity level,
especially in children. The present study was aimed to assess the physical activity pattern in
children using the Tracmor2 accelerometer. Tracmor2 has been proven to be a reliable
method to measure physical activity patterns (7). Compared to other accelerometers,
Tracmor2 is a small (7 x 2.8 x 0.8 cm) and light (30 g) device, which optimizes subject
comfort (11).
In the present study among children it was found that the fraction of time spent on
moderate intensity activities did not contribute significantly to PAL, unlike the fraction spent
on low and high intensity activities. In contrast to the findings in adults, where the amount
of overall physical activity can be increased by expanding the amount of time spent on
activities of moderate intensity and reducing low-intensity activities (9), children should be
stimulated to perform more high intensity activities because those activities belong to their
habitual activity pattern.
Comparing physical patterns of children to those of adults and the elderly shows that the
children spend more of their active time on high intensity activities. Young adults spend an
average of 9% of their active time on high intensity activities, while the corresponding
percentage among the elderly was found to be 4%. In contrast, the present study found
that children spend an average of 19% of their total active time on high intensity activities.
The difference in time spent on high intensity activities between children and adults reflects
the different activity patterns among children, which are characterized by short,
intermittent bouts of vigorous physical activity (3, 12-14). Probably because of their lower
body weight it is easier for children to perform high intensity activities.
Even though children spend more time on high intensity activities, the PAL values we found
among children were lower than those reported for young adults and the elderly. In
addition to the fact that because of their lower body weight, high-intensity activities costs
them less energy, this can probably be explained by the difference in the amount of sleep.
Chapter 4
Physical activity pattern of children assessed by W-axlal acceleromctiy
59
The children slept an average of 11.2 hours a day, while adults have been found to sleep
for an average of 8.3 hours, implying a longer total activity time for adults.
It would be of interest to measure the physical activity pattern of obese children using the
Tracmor2 and to compare those with the activity pattern of healthy children. Because we
found PAL to be influenced by changes in low and high intensity activities in children, a
decreased amount of time spent on high intensity activities is expected in obese children.
If this would appear to be true, health programs should be aimed at educating parents of
obese children to stimulate their children to perform more high intensity activities (playing
outside) instead of low intensity activities (playing computer games).
Because we found a discrepancy between the activity patterns of children and young
adults, health strategies should be aimed at preventing children's activity patterns from
changing into those of the adult population (involving less high-intensity activity) by
educating them about the importance of regular physical activities like walking or cycling.
In conclusion, our observations suggest that to obtain a higher PAL in children, children should
be given the opportunities to perform high-intensity activities. In addition, children should be
educated about the importance of regular physical activity to prevent inactivity in adulthood.
Figure 4b
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ABSTRACT
Purpose
Parents of children treated with growth hormone (CH) frequently report to the pediatrician
that their children have become more physically active. In the present study activity
patterns of GH-treated children were measured and compared to those of healthy controls.
Methods
Subjects were 25 children at the start of CH treatment (age 8.4 ± 2.6 years) and 19 age
and gender matched controls (age 8.8 ± 3.2). Physical activity was assessed with a tri-axial
accelerometer for movement registration over two separate 2-week intervals, one before
the start of GH treatment and one two weeks after the start of treatment. GH-treated
subjects were categorized as poor responders (change in height over 1 year < 0.7 SDS,
n=15) or good responders (change in height over 1 year > 0.7 SDS, n=10).
Results
Before therapy, good responders showed a significantly lower physical activity compared to
healthy controls, spending significantly less time on high-intensity activities. This difference
was disappeared two weeks after the start of therapy. Physical activity in poor responders
was not significantly different from controls before and after two weeks of GH therapy.
Conclusion
Children who respond well to GH therapy (change in height > 0.7 SDS) showed increased
physical activity after two weeks of therapy as assessed with a tri-axial accelerometer.
Chapter 5
Physical activity in children receiving growth hormone therapy as measured by tri-axial accelerometry
INTRODUCTION
Since the FDA approved the use of recombinant growth hormone (rGH) in 1985, the
number of prescriptions of growth hormone has risen dramatically (1). It was no longer
only severely growth hormone deficient (GHD) patients who were treated, but also children
suffering from partial GHD. The eligibility of patients for GH treatment is decided on the
basis of anthropometric parameters and endocrine testing.
In pediatric patients growth hormone therapy is used to correct height deficit. However, it
is also remarkable that parents frequently report to physicians that their child has become
livelier after the start of treatment. This may be based on metabolic effects of GH as have
been described in the literature. Gregory et al. for example found a significant increase in
basal metabolic rate (BMR) (2) and total daily energy expenditure (TDEE) in children
receiving GH therapy.
An increase in TDEE can be attributed to growth as well as to increased physical activity.
Possible changes in this component of TDEE can be measured by accelerometry.
Accelerometers measure the occurrence and intensity of body movements. The method is
easy applicable and does not interfere with the child's daily activities. Two kinds of
accelerometers are distinguished: one-axial and tri-axial accelerometers. One-axial
accelerometers measure accelerations in one direction in contrast to tri-axial
accelerometers, which measures accelerations of the body in three dimensions.
Since data about physical activity patterns in children receiving GH therapy are lacking, the
present study investigated the short-term effect of GH on spontaneous physical activity. For
this purpose, the Tracmor, a tri-axial accelerometer, which has been proven to be a reliable
tool for the assessment of physical activity (3, 4) has been used. The patients were divided
into two groups (good responders and poor responders) according to their response to GH
therapy, to see whether the short-term changes in activity patterns were comparable
between the two groups. In addition to the intensity of physical activity, Tracmor data have
been used to calculate the fraction of time spent on a given activity at low, moderate or
high levels of intensity (3, 4).
METHODS
Subjects
Eligibility for therapy was based solely on one or more anthropometric criteria as visible in
GH deficient patients: height SDS at start of treatment < -2.5 SDS, deviation from target
height > 1.3 SDS and growth in the year before treatment > -0.25 SDS. Additional,
endocrine testing was performed (arginine, clonidine and sleep test) to measure maximum
GH concentrations.
To minimize the influence of environmental factors, healthy controls were selected from
friends or relatives of the patients living in the same neighborhood. They were measured
simultaneously with the patients, but did not receive GH therapy. Parents and children were
informed about the study and written informed consent was obtained. The study was
approved by the Ethical Committee of the University hospital Maastricht.
Twenty-five children started GH therapy of whom, 19 had a height below -2.5 SDS, 21
deviated more than 1.3 SDS from their target height and 9 children showed a deviating
growth. All patients were prepubertal by physical examination. Two control patients were
already pubertal
Study design
The Tracmor was worn twice (M1 and M2) during a two weeks period, before the start of
therapy in the patients and during weeks three and four of this therapy. The children
received 0.7 mg hGH/m^/day (Humatrope®). Two girls with Turner syndrome received 1.3
mg hGH/m^/day (Humatrope®), in accordance with Dutch treatment criteria. After one
year, growth was evaluated and expressed as z-scores (SDS) (5). The difference in SDS
(SDS,, - SDS,Q) was used to divide the patient group into good and poor responders. A
change in SDS > 0.7 was considered to be a good response, based on the mean response
to GH therapy found in the study by Ranke et al. (6).
Physical activity
The physical activity was assessed with the help of a tri-axial accelerometer for movement
registration (Tracmor, Philips Research, Eindhoven, The Netherlands). The Tracmor is a small
device (7 x 2.8 x 0.8 cm), which is worn on a belt at the back of the waist. The tri-axial
accelerometer calculates the sum of the rectified and integrated acceleration curves from
the anteroposterior, mediolateral and vertical directions of the trunk. The integration period
was set at 1 min and the final output is expressed as counts per minute (c.p.m.) (3).
The Tracmor was worn during waking hours, except while showering and during
swimming. The parents of the children recorded in a log the times when the children woke
up, when they put the Tracmor on and off and when they went to bed. If the sum of the
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time during which the device was worn and the duration of sleep was less than 22 hours,
the day was excluded from the analysis (mean number of recorded days was 11).
Activities were defined at three intensity levels, as described before (3, 4), Low-intensity,
associated with an accelerometer output < 200 c.p.m, represents lying, sitting and standing.
Moderate-intensity, associated with an accelerometer output ranging from 200 to 500
c.p.m, includes walking at a velocity of 1.5-2.0 km/h. High-intensity activities are
associated with an accelerometer output > 500 c.p.m. The fraction of time spent at a given
intensity level was calculated as the time spent at this intensity level divided by total activity
time.
STATISTICS
Tracmor data were expressed as counts/min, mean Tracmor counts per day were divided
by the time during which the device was worn, to correct for possible differences in activity
time. For each group of children, a paired t-test was used to see if there was a significant
difference in the Tracmor data before and after two weeks of therapy. The treated groups
were compared with each other and with the control group using an independent t-test.
RESULTS
The mean growth response after one year for the entire growth hormone treatment group
(n=25) was +0.59 SDS (±0.45), while the change in SDS in the control group was +0.02
(±0.21). On the basis of the response to GH therapy, three groups could be distinguished:
• control group (n=19)
(mean age 8.8 ±3.2 years, weight 28.1 ±11.0 kg, height 1.3 ± 0.2 m);
• patient group with a response to CH therapy < 0.7 SDS/year (n=15)
(mean age 9.7 ± 2.4 years, weight 23.6 ± 5.9 kg, height 1.2 ± 0.1 m);
• patient group with a response to GH therapy > 0.7 SDS/year (n=10)
(mean age 6.5 ± 1.7 years, weight 17.1 ± 7.4 kg, height 1.1 ± 0.09 m).
Although the mean age of the two patient groups did not differ significantly from that of
the controls, the children with a poor response to GH therapy were significantly older than
the good responders (9.7 ± 2.4 versus 6.5 ±1.7 years; p< 0.01). The number of recorded
days did not significantly differ between the two measurement periods.
As can be seen in table 5a, the number of Tracmor counts/min before the start of the GH
therapy was significantly lower in the good responders than in the controls (p< 0.05). After
two weeks of therapy, this difference had disappeared, because of a significant increase in
the number of counts/minute among the good responders (p<0.05) (table 5a).
The proportion of time the three groups spent on low, moderate and high intensity activity
is listed in table 5a. This shows that before therapy, good GH therapy responders spent less
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Table 5a Tracmor date output of tfiree sub/ecf groups: contro/s, poor GH responders
("change /n he/gbf < 0.7 SDSJ and good CH responders ("change /n he/gbt > 0.7 SDSJ.
Tracmor
(Counts/min)
Low activity
(%)
Moderate activity
(%)
High activity
(%)
Controls
M1
6 1 *
(17)
56
(10)
25
(6)
19*
(7)
M2
57
(17)
56
(12)
25
(6)
19
(8)
Poor
M1
67*
(16)
56
(11)
23
(5)
21*
(7)
responders
M2
64
(15)
58
(11)
23
(5)
19
(7)
Good
M1
48"
(11)
62
(8)
25
(6)
13"
(5)
responders
M2
* 55
(12)
58
(11)
26
(6)
* 17
(7)
A/I7 = first measurement per/od, before start of CH treatment /n the paf/ents.
A/I2 = second measurement per/od, two weeks after the start of CH treatment /n the pat/ents
va/ues are means Csd). Tracmor data were expressed as counts/m/n, mean Tracmor counts
per day were d/V/ded by the t/me dur/ng wb/ch the dewce was worn, to correct forposs/b/e
d/fferences /n act/wty t/me.
A pa/red t-test was used to see /f there was a s/gn/ficanf d/fference /n the Tracmor data
before and after two weeks of therapy ("stars f* p< 0.05J denote w/fb/n groups d/fferences
compared to base//ne va/uesj.
An /ndependenf t-fest was used to test the d/fference between the three d/fferent pat/ent
groups ("uppercase /etters represent between groups d/fferences, means w/th d/fferent
/etter superscr/pts are s/gn/ficant/y d/fferent p<0.05,).
time on high-intensity activities than controls and poor responders (p<0.05, p<0.01
respectively). After two weeks of CH therapy, there was no longer a significant difference
between the three groups. Good GH therapy responders showed a significant increase in
high-intensity activities (p<0.05). Tracmor data of poor GH responders did not significantly
differ from controls before as well as after start of therapy. Excluding the Turner patients
did not influence the outcome of the results.
A comparison of the two patient groups in terms of the maximum growth hormone values
found during the endocrine tests revealed no significant difference between the good and
poor responders as regards the maximum GH concentrations found during the sleep,
arginine or clonidine tests.
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DISCUSSION
Growth hormone is known to have an anabolic effect, which is associated with increased
energy expenditure (7). Although it is a general experience of pediatricians that children
become more active after the introduction of GH therapy, Gregory et al. were unable to
demonstrate an increase in activity. The measured increase in TDEE in their study reflected
the increase in BMR (2).
In the present study, the children were divided into two groups according to their response
to growth hormone therapy. Before the start of GH therapy, good GH therapy responders
showed a lower number of Tracmor counts per minute and spent less time on high-intensity
activities. The observed difference had disappeared after two weeks of GH therapy. This
means that children with a good response on GH therapy were less physical active than
healthy controls until GH was supplemented. The lower amount of activity before start of
treatment might be partly explained by an impaired erythropoiesis, as was demonstrated in
GHD adults (8). Erythropoiesis increases during GH therapy, which may lead to an increase
in oxygen capacity and thereby contribute to an improved exercise performance capacity (8,
9). In addition an increase in plasma volume and total blood volume, as was measured in GH
deficient adults on GH therapy (8, 10), might contribute to an increase in VO^^^ (11).
However, as the present study showed, the amount of spontaneous physical activity
differed between good and poor responders. In contrast to the good responders, poor
responders were comparable to controls before start of GH treatment. GH therapy did not
influence their activity patterns. Probably, in these children their retarded growth was not
based on growth hormone deficiency. The present results show that additional exogenous
GH therapy does not influence activity levels in these children in contrast to the good
responders in which GH therapy causes an increase in growth and physical activity. Our
finding in poor responders might explain the results on activity found by Gregory et al. (2).
This study found an increase in TDEE, which reflected the increase in BMR. Perhaps the
heterogeneity of the patient group in their study in terms of the severity of GH deficiency
could explain why the average effect of GH treatment on activity was not significantly
different.
The effect of GH therapy on activity was observed over a relatively short period of time
because metabolic effects of GH therapy become apparent soon after its start (10, 12), as
was confirmed in the present study. The good responders adapted similar activity levels as
their control counterparts after two weeks of GH supplementation. However, it would have
been of interest to measure physical activity after one year of therapy to see if the increase
in physical activity in the good responders was maintained. Unfortunately this was not
possible because of practical limitations and should be subject of future studies.
In the present study, intensity of physical activity was measured using a tri-axial
accelerometer, which is a non-invasive method to measure activity under free-living
conditions. It confirmed the increase in activity reported by some parents after the
introduction of GH therapy. Good responders were less active than controls before the
introduction of GH therapy, which was normalized two weeks after the start of therapy. In
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the poor responders group, CH therapy had no effect on activity. The increase in physical
activity in responders was mainly attributable to an increase in high-intensity activities.
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ABSTRACT
Aim . - . . . . - , - . . r
To see if there is an increase in endurance time and grip strength in children receiving
growth hormone (GH) therapy.
Methods
Subjects were 27 children starting GH treatment for medical treatment (age 8.8 ± 2.8 years)
and 22 matched controls (age 8.5 ± 3.2). Endurance time on a treadmill and grip strength
were measured before and during one year of GH therapy. In addition, height, weight and
total body water (TBW) were measured. After one year of therapy GH-treated subjects
were categorized as poor responders (change in height < 0.7 SDS) or good responders
(change in height > 0.7 SDS).
Results
Only in the good responders there was a significant increase in endurance time. Height and
TBW were both strongly correlated to the endurance time in the controls. Although
significant, this relation was weaker in the patient groups. Grip strength increased in all
three groups and was significantly correlated to weight and TBW with comparable R-
squares.
Conclusions
After one year of GH therapy, endurance time had increased in children with a good
response on GH therapy. GH caused an additional effect on endurance time besides height
and TBW. Grip strength had also increased, but no more than in an age matched group of
healthy children.
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INTRODUCTION
Growth hormone (GH) has been used for 40 years to promote linear growth in GH-
deficient children. Treatment is usually being stopped when final height is reached.
However, GH also has a metabolic effect, reflected in an increase in fat-free mass and
energy expenditure (1, 2). In GH-deficient adults, these metabolic effects are the only
reason to supply GH.
Additionally, effects on cardiac function have also become clear in this patient group (3).
GH-deficient adults were found to have impaired cardiac function (4, 5), which improves
after the introduction of GH therapy (4, 6-8). In addition to improved cardiac function,
increased exercise tolerance (9, 10) and muscle strength have been reported, which might
improve physical fitness and the ability to perform everyday task. Because of these
potential benefits for physical performance capacity, the International Olympic Committee
(IOC) has put GH on the doping list.
The present study examined the effect of GH therapy on physical fitness and grip strength
in children by means of an exercise test and a handgrip test. It was expected that the
endurance time (Tend) and grip strength (Grip) increased in comparison with healthy
controls, especially in children who showed a good response on GH therapy. Height, weight
and body composition were measured to explain possible changes in Tend and Grip.
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METHODS
Subjects
The children were considered eligible for GH therapy if they showed at least one of the
following signs of GH deficiency:
• height SDS at start of treatment < -2.5 SDS;
• deviation from target height > 1.3 SDS;
• growth in the year before treatment > -0.25 SDS, and
• low GH concentrations in an arginine and clonidine provocative test. The endocrine
tests were not decisive for therapy.
The study included 27 children with an average age of 8.8 (± 2.8) years who were starting
GH treatment, while 22 healthy children aged 8.5 (± 3.2) years were included as controls.
The controls were friends or relatives of the patients, living in the same neighborhood. They
were measured simultaneously with the patients, but did not receive GH therapy. Parents
and children were informed about the study before informed consent was obtained. The
study was approved by the Ethical Committee of the University hospital Maastricht.
Study design
Endurance time and grip strength were measured immediately prior to the treatment, at 2
and 6 weeks and at 3, 6, 9 and 12 months after start of therapy (Tend,, ...Tend ,7 and
Grip,,...Grip ,p. All measurements were performed by the same investigator (MH). GH
supplementation was 0.7 mg Humatrope®/m^/day. Two girls with Turner syndrome
received 1.3 mg Humatrope®/m^/day, in accordance with Dutch treatment criteria. After
one year, growth was evaluated and expressed as standard deviation scores (SDS) (11). The
difference in SDS (SDS^-SDS,,) was used to divide the patient group into good and poor
responders. A change in SDS > 0.7 was regarded as a good response, based on the mean
response to GH therapy found in the study by Ranke et al. (12).
Treadmill test
Treadmill exercise testing was performed using the Bruce treadmill walking protocol to
voluntary exhaustion on a Jaeger LE2000 treadmill (Erich Jaeger, Höchberg, Germany). The
Bruce walking protocol consists of seven 3-minute stages.
• Stage 1: 2.74 km/h at a slope of 10%;
• Stage 2: 4.02 km/h at a slope of 12%;
• Stage 3: 5.47 km/h at a slope of 14%;
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• Stage 4: 6.76 km/h at a slope of 16%;
• Stage 5: 8.05 km/h at a slope of 18%;
• Stage 6: 8.85 km/h at a slope of 20%;
• Stage 7: 9.66 km/h at a slope of 22% (13).
The children were not allowed to use the guardrails, except for the children younger than
6 years, and during a change stage, in order to maintain balance. They were encouraged
to push themselves to maximum performance. The test was terminated when the children
indicated they really wanted to stop, despite encouragement. Maximum endurance time
was recorded (Tend).
Grip strength
Grip strength (Grip,, to Grip,.,), the isometric muscle force of the hand and forearm, was
measured in the dominant hand with a hand-held dynamometer (JAMAR) adjusted for grip
size. Measurements were performed three times, after which mean values were calculated.
To elicit maximum effort, verbal encouragement was given during the performance of each
test.
Body composition
Total body water (TBW) was measured with the stable isotope of hydrogen. The water is
labeled on the hydrogen atom. Before the administration of the dose a background sample
was taken to determine the natural abundance of the urine. The children drank the water
in the evening before they went to bed. The other morning a urine sample was taken after
the first voiding. In this urine sample the concentration label was determined. The
calculation of the total body water is as follows:
C1 * V1 = C2 * V2
C1 = the concentration of the tracer in the ingested fluid
V1 = the volume of the dose
C2 = the concentration of the tracer in the sample
V2 = distribution volume in the body
Due to the exchange of the label with non-aqueous substances in the body, V2 has to be
divided by 1.04 to determine TBW.
The two first measurements were performed at the hospital to teach the parents the
procedure. The children visited the hospital before their habitual bedtime. First the baseline
urine was taken, whereafter the deuterium was ingested. The bottle which contained the
deuterium was rinsed thoroughly, to be sure all water was ingested. The following morning
the children returned to the hospital and a second urine sample was collected.
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Because the hydration of the fat free mass, which in adults is assumed to be 73% is in
children age-dependent (14) the variable TBW was used for analyzing the effect of TBW
on Tend and Crip.
STATISTICS
Children for whom baseline or one-year data were missing were excluded from the
analysis. Other missing values were supplemented using the mean value of the preceding
and subsequent measurements. If there were more than two missing values, the patient's
data were excluded. Baseline and one-year values were compared between the different
groups using an unpaired t-test. A one-factor ANOVA of repeated measures was
performed for each group on Tend „...Tend ,7 and Grip „...Grip ,7 to see if there was a
significant change during the treatment year. On significant outcomes, a Scheffe post hoc
analysis was used to determine the significant differences.
Regression analyses were performed per group on data of all time points to evaluate the
effect of height and TBW on Tend and TBW and weight on Grip.
RESULTS
Of the children who started treatment, three were excluded because of missing baseline or
final values. One child (and the corresponding control) stopped because of recurrence of a
pituitary tumor. A further three poor responders and three controls had to be excluded from
the handgrip analysis because of missing data. Anthropometric baseline data are given for
all children in whom Tend was measured (table 6a). Mean height (expressed as SDS or cm),
weight and age of the children for whom Tend (n=49) was obtained did not differ from
those of the group of children for whom grip strength was obtained (n=43).
On the basis of the response to GH therapy, three groups could be distinguished:
• control group (n=22) (mean age 8.5 ± 3.1);
• patient group with a response to GH therapy < 0.7 SDS/year (n=16) (mean age 10.4 ±
2.4);
• patient group with a response to GH therapy > 0.7 SDS/year (n=11) (mean age 6.4
±1.2).
The division of the controls into two groups on the basis of the response to GH therapy of
their age matched control (to exclude the differences in age) did not show a change in
results, therefore the results of the control group were taken together.
Poor responders were significantly older than good responders and controls. Height
expressed as SDS was significantly lower in both patient groups, before as well as after
therapy, compared to controls (table 6a).
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There was no difference in height (expressed in centimeters) between controls and poor
responders before and after therapy. Good responders were significantly shorter (height
expressed as centimeter) than the other groups both before and after therapy. GH
concentrations found in the arginine and clonidine test did not differ significantly between
the two patient groups.
Maximum endurance time (Tend):
Figure 6a presents the changes in Tend over the year. Endurance time was significantly
lower in the good responders than in both of the other groups, but after one year the good
responders were comparable to controls. Poor responders showed longer endurance time,
before and after the start of therapy, than good responders (table 6a). Compared to
controls, poor responders started at the same level, but after one year they showed longer
endurance time.
The repeated measures ANOVA for Tend was only significant in the good responder group.
Post-hoc analysis showed that this significance was accounted for by the increase after
6 months (p< 0.0001)
Height as well as TBW were significantly correlated to Tend. However the relation was
strongest for the controls (table 6b).
Figure 6a
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Table 6a Paf/ent character/st/cs.
Age (years)
Height SDS„
Height SDS ,7
[GH] mU/l arginine test
[GH] mU/l clonidine test
Tend,, (min)
Tend,7 (min)
Grip,, (kg)
Grip,, (kg)
Controls
8.5 (0.7)*
-1.0(1.1)*
-0.9 (1.1) C.E
9.6(2.2)*
9.7(1.7)C
13.7 (5.9) c
15.2 (6.4) c
Poor
Responders
10.4(2.4)8*
-2.8(1.0)**
-2.4(1.0)0
20.8
39.6
10.6(1.8)*
11.3 (1.4)0*
14.2 (5.8) c
16.8 (6.5) c
Good
Responders
6.4(1 .2)8*
-3.7 (0.7) *•«
-2.6(0.7)*
21.6
32.3
7.9 (1.0) 8*
9.5(0.8)*
7.4(2.1)0
9.1 (1.5)0
*"p< 0.05; CDp <0.07; "
GH = growth hormone
0.0007
Grip strength
A significant increase in grip strength occurred in all three groups (figure 6b). Grip „ and
Grip,., were significantly lower in the good responder group than in controls and poor
responders. Grip was in all three groups correlated to weight. The weight of these
correlations was for all three groups comparable (table 6b).
Table 6b «-squares between Tend and he/ght and 7B W, and Gr/p and we/ght and 7BW for
contro/s, poor responders and good responders.
Controls Poor responders Good responders
Tend- height
Tend -TBW
Grip -Weight
Grip -TBW
0.55
0.49
0.71
0.67
0.08
0.04
0.76
0.74
0.31
0.29
0.52
0.63
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DISCUSSION
The present study evaluated the effect of GH therapy on endurance time and grip strength
in children receiving GH therapy for medical treatment. The treated patients were divided
into two groups according to their response to GH therapy. Prior to the treatment, the good
responders (change in height > 0.7 SDS) had a shorter endurance time, which increased
significantly and matched the control values after one year of therapy. Grip strength
increased in all three groups.
Because height was significantly correlated with endurance time, it may serve as a partial
explanation of the increase in endurance time. An increase in height and leg length caused
by GH therapy makes a walking test easier to perform. Cuneo et al. corrected exercise
capacity for changes in muscle mass and found no alterations from baseline (15). This
suggests that the increase in exercise performance is mainly caused by GH-associated
changes in muscle mass.
However the correlation between height and TBW and Tend was weaker for the good
responders and even more weaker for the poor responders, which indicates that other
factors must have influenced Tend.
Figure 6b
A/lean Cr/p sfrengt/7 (Cr/p,) and standarddev/afron /n confro/s ("fr/ang/es,), poor responders
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There is another reason to assume that height can only partly explain the increase in
endurance time. Although the good responders had the same endurance time as the
controls after one year of therapy, their height was still significantly lower.
The additional effect of GH can be accounted for by the metabolic effects of the hormone.
Effects of GH on cardiac function have been described. In rats, the expression of the GH
receptor gene was found to be stronger in the myocardium than in other tissues (16). GH
also stimulates IGF-1 mRNA expression in the rat heart and skeletal muscle (17, 18).
Furthermore, there is evidence of a stimulatory effect of IGF-1 on cultured cardiomyocyte
growth (19). An additional explanation is the known increase in erythrocyte mass or oxygen
transport capacity caused by a stimulatory effect of IGF-1 on erythropoiesis (20-23).
However, research in children found no association with changes in echocardiographic
parameters of left ventricular size and function when these parameters were corrected for
changes in body size (24-27). More research should be performed to see if changes in
oxygen transport capacity lead to a better endurance time in children receiving GH therapy.
In the present study, grip strength was much lower in good responders than in controls and
poor responders. This can probably be attributed to the difference in weight, while weight
was in all groups a significant predictor for the grip strength. From the present data it
cannot be concluded that there is an additional effect of GH on grip strength, because
handgrip strength showed comparable increases in all groups. Also, there was no difference
in the correlation between weight or TBW and Grip, suggesting that the most important
cause of the increase in grip strength is the increase in weight and TBW caused by normal
growth.
In muscle force generation, the maximum tension of a muscle is considered to be
proportional to its cross-sectional area (28). However, it has been shown in acromegaly
patients that an increase in muscle mass did not necessarily result in greater muscle strength
(29). While GH-induced muscle enlargement does occur in the absence of muscular work,
it does not appear to increase the amount of contractile protein, thus producing no
enhancement of muscular strength (30).
In a recent study (M. Hoos, submitted for publication) we showed that the amount of time
children with a good response to GH therapy spent on high intensity activities like running
was increased by the therapy. This might cause a neurogenic training effect on the leg
muscles, which would provide a possible explanation for the fact that an additional effect
was seen on Tend of GH.
The present study measured endurance time and grip strength in young children, which
implies some caveats. First, it would have been ideal to have measured oxygen
consumption as a measure of physical fitness. This procedure, however, is difficult to
perform in young children, and might have led to decreased compliance. Second, it is
sometimes hard for children to demonstrate maximum performance. The control group was
included to partly correct for this bias. All children were encouraged in the same way by the
same investigator.
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In summary, the present study evaluated the effect of GH therapy on endurance time and
grip strength in children receiving GH therapy for medical treatment. It was shown that
endurance time had increased in children with a good response to GH therapy after one
year of therapy. Although grip strength had also increased, this increase was not different
from that which can be expected in age-matched children.
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ABSTRACT
The objective of this study was to investigate whether short-term changes in metabolism,
as a result of growth hormone (GH) therapy, could be used to predict its growth effect after
one year.
Twenty-eight children (8.7 ± 2.8 years) were selected, based on anthropometric criteria
characterizing GH deficient patients. In addition, 21 healthy age- and sex-matched controls
(8.9 ± 3.1 years) were included. Total body water (TBW) and height were measured before
and at six weeks and one year after the start of treatment. After one year of treatment,
patients were divided into good and poor responders based on a change in height of at
least 0.7 standard deviationscore (SDS).
Because individuals of different heights were compared, changes in TBW after six weeks
were corrected for height^ in accordance with the Body Mass Index. Eighty percent of the
children who showed a good response to GH therapy had a change in TBW divided by
height^ exceeding the 2 SD reference line of the controls. In contrast, poor responders did
not differ from controls. Maximum GH concentrations found during endocrine tests were
not significantly different between good and poor responders.
Changes in body composition data, after six weeks, proved valuable in identifying good
responders to GH therapy.
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INTRODUCTION
Growth hormone (GH) therapy is prescribed to correct height deficits in children whose
own GH secretion is insufficient. Although the diagnosis and prediction of the effect of GH
therapy on growth cause few problems in severely GH-deficient patients, difficulties arise
with children suffering from partial growth hormone deficiency. The outcome of endocrine
tests in these patients is not discriminative and does not adequately predict the effect of
therapy on growth. In addition, height measurement over a period of one year is required
for a reliable evaluation of the growth response. The drawbacks of daily injections and high
therapy costs are further reasons to try and find other ways to improve diagnosis and
prediction in the short term.
Besides its growth-promoting effect, GH also influences metabolism in adults (1-3) as well
as in children(4-8), producing changes that have been found to be related to changes in
height (9, 10).
In view of this, the present study investigated whether short-term changes in metabolism
as a result of GH therapy, could be used to predict its growth effect after one year. Body
composition changes were measured six weeks after the start of GH therapy in 28 children
and 21 age-matched controls without therapy. The patients were included purely on
anthropometrical indications, the outcome of the endocrine tests not being decisive to start
therapy. Growth was evaluated through the first year of therapy, after which children were
classified as good or poor responders to GH therapy. Our hypothesis was that changes in
body composition exceeding those found in the control group would occur only in patients
with a good response to GH therapy.
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SUBJECTS AND METHODS
Subjects
Eligibility for therapy was based solely on one or more of the anthropometric criteria
characterizing GH deficient patients:
• height at the start of treatment less than -2.5 SDS;
• deviation from target height more than 1.3 SDS;
• deviation of growth in the year before treatment more than -0.25 SDS.
Children were excluded if other reasons than those related to GH for growth retardation
were present. Because it is known that girls with Turner syndrome show a growth response
to GH therapy, they were included in the analysis. To minimize the influence of
environmental factors, age and sex-matched healthy controls were selected from friends or
relatives of the patients living in the same neighborhood. They were assumed to be healthy,
normally growing children, based on anamnestic information from the parents. The controls
were measured simultaneously with the patients, but did not receive GH therapy. Parents
and children were informed about the nature of the study and written consent was obtained.
The study was approved by the Ethical Committee of the University Hospital Maastricht.
Of the 30 children who started treatment, two were not included in the analysis. One child
(and the corresponding control) was excluded because of recurrence of a pituitary tumor.
Another child was excluded because of missing data. As a result, 28 children, with a mean
age of 8.7 (± 2.8) years, suspected of being GH-deficient, and 21 healthy age-matched
controls (8.9 ± 3.1 years of age) were included in the study. Height SDS at start of the
study was -3.12 (± 0.9) for the patient group and -0.91 (± 1.2) for the control group.
Of the 28 children suspected of being GH-deficient, 21 had a height below -2.5 SDS, 25
deviated by more than 1.3 SDS from their target height and 10 children showed a deviating
growth chart. All patients, including one late-presenting Turner patient aged 16 years, were
prepubertal by physical examination. Two control patients were already pubertal.
Study design
All measurements were done by the same investigator (MB. Hoos). Before treatment was
started, three endocrine tests were performed in the patient group to measure maximum
serum GH values. The patients received 0.7 mg Humatrope®/W/day. Four girls with Turner
syndrome received 1.3 mg Humatrope®/nWday, in accordance with Dutch treatment criteria.
Height and weight were measured at the start of therapy, at six weeks and then every three
months, up to a total of one year. Height was expressed as standard deviation score (SDS).
The difference in SDS over one year (SDS,, - SDS ,^) was used to divide the patient group
into good and poor responders. A change in SDS more than 0.7 was considered to be a
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good response, based on the mean response to GH therapy found in the study by Ranke
et al (11).
As a metabolic effect parameter, total body water (TBW) was measured with the deuterium
dilution technique before and at six weeks and one year after the start of therapy. TBW was
used instead of fat-free mass because the hydration level of the fat-free mass, which in
adults is assumed to be 73%, is age-dependent in children (12).
To interpret TBW in individuals who differed in height, the results were corrected for height
(13-15) as TBW/height*.
Height
Height was measured using a stadiometer. After shoes and socks had been removed, body
height was measured, exerting a gentle upward pressure on the mastoid processes, so that the
child was fully extended (16). A weight of 0.5 kg was placed on the headboard in order to
flatten the child's hair and enable the physician to keep the child in the correct upright position.
Deuterium dilution method
TBW was measured with the stable isotope of hydrogen, according to the Maastricht
protocol (17). The water was labeled at the hydrogen atom. Before the dose was
administered, a background sample was taken to determine the natural abundance of
deuterium in the urine. The children drank the water in the evening before they went to
bed. The next morning, a urine sample was taken after the first voiding. Total body water
was calculated as follows:
Ci " V, = C, • V,
C, = concentration of the label in the ingested fluid
V, = volume of the dose
Cj = concentration of the tracer in the sample
Vj = distribution volume in the body
Due to the exchange of the tracer with non-aqueous substances in the body, Vj had to be
divided by 1.04 to determine TBW (17).
Endocrine tests
A/g/n/ne tesf
The arginine test was performed in the morning after an overnight fast. Arginine hydrochloride
(0.5 g/kg) was infused for 30 minutes. Blood samples were taken to measure growth hormone
levels at -15, 0, 30, 45, 60, 75, 90 and 120 minutes after the start of the infusion (18).
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C/on/d/ne terf
The clonidine test was performed in the morning after an overnight fast. After an oral dose
of clonidine (0.15 mg/m*, max. 0.15 mg), blood samples were taken every 30 minutes for
the next two hours to measure growth hormone levels (18)
S/eep/ng tesf
Because natural peaks of growth hormone secretion occur during the first hours of sleep,
blood samples were taken every 10 minutes during the first two hours of sleep to measure
growth hormone levels.
Growth riormone ana/ys/s
The AutoDELFIAhGH assay (Wallac, Inc., Turku, Finland) was used to establish growth
hormone concentrations in serum (CV= 3.5%, lower detection limit = 0.03 mU/l).
Calculations
TBW data of the control group were plotted against height at the start of the study, at six
weeks and at one year, to evaluate the relation between height* and body composition. A
reference line was constructed from the baseline data.
The intra-individual difference in body composition of the controls at the start of the study
and at six weeks thereafter was used to estimate the limits of normality.
The difference in TBW between t^ en t g ^ ^ , divided by height*, was plotted against the
change in height SDS after one year of CH therapy (figure 7c). This graph was then used
to calculate the sensitivity and specificity of the body composition measurement for the
prediction of the effect of GH therapy on growth.
RESULTS
Patient characteristics are given in table 7a. Figure 7a shows the correlation between TBW
and height* for the control group at the start of the study (TBW = 3.5 * (height*)* - 0.95*
height* + 6.83 (Rsq=0.97)). The plotted data of the measurements taken at six weeks and
one year were not significantly different from the data expected according to the reference
line based on baseline data. A two-sample t-test found no significant difference in TBW/
height* at the start of treatment between controls and poor responders, whereas good
responders showed a significantly lower TBW/height* at the start of treatment (p<0.05).
In the control group, the mean difference in TBW between t(, en t g ^ ^ divided by height*
was 0.39, with a standard deviation (SD) of 0.27. The use of two standard deviations
resulted in an upper limit of 0.93 l/m*.
Figure 7b shows the change in TBW over six weeks divided by height*, plotted against the
change in height during one year (SDS) for all children. Two reference lines are shown. The
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Figure 7a
Re/at/on between 7ofa/ body water (TßWj and he/gnf^ for nea/tny ch/Wren at start of study
(o,) after 6 weete (•,) and 7 year (A,). Reference //ne /s based on base//ne data.
CO
10 -
0.5
Height^
reference line on the x-axis represents a change in SDS,^ of 0.7, which is the cut-off value
chosen between good (n=10) and poor responders (n=18). The reference line on the y-axis
indicates the mean change in TBW divided by height^ of the control group plus two times
the standard deviation of this value (0.93
Eighty percent of the children who showed a good response to GH therapy had a change
in TBW/height^ exceeding the 2 SD reference line of the control group. In contrast, the
Table 7a Sub/ect cnaracter/st/cs.
Age (years)
Sex (M:F)
Height before
Height after 1
Weight before
Weight after 1
therapy (SDS)
year of therapy
therapy (kg)
year of therapy
(SDS)
(kg)
Controls
n=21
8.9 (±3.1)
(10:11)
-0.91 (±1.2)
-0.86 (± 1.2)
27.9 (± 10.0)
31.3 (±11.2)
Patients
n=28
8.7 (±2.8)
(14:14)
-3.12 (±0.9)
-2.53 (± 0.8)
21.7 (±9.4)
25.0 (± 9.9)
(Va/ues are means ± standard dewat/on. A/l:ma/e; F: fema/ej
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Figure 7b
C/iange in 7BW over 6 weefo d/V/ded £>y height^, p/otted against change in SDS after 7
year for nea/fhy confro/s (AJ good responders ("•,) and poor responders To/
2.0
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1 . 0 -
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Change in height over 1 year (SDS)
poor responders did not differ from the control group. The good responders showed a
significantly higher change in TBW/height^ than the poor responders as tested by an
unpaired t-test (p<0.01). Based on the chosen cut-off values, the specificity of TBW
change/height^ was 88% and the sensitivity 89%. The Turner patients were all in the non-
responding quadrant and did not deviate from controls and poor responders.
Good responders were indistinguishable from poor responders with regard to the outcome
of the endocrine tests (figure 7c). Figure 7c shows the maximum GH concentrations found
during the three endocrine tests before the start of therapy. The reference line on the x-axis
indicates the difference between good and poor responders. A second reference line, on
the y-axis, indicates a growth hormone concentration of 20 mU/l. This value is usually
taken as the maximum value found in GHD children.
The good responders had the following mean maximum values on the three endocrine
tests: 20.8 (±7.4) mU/l for the arginine test, 36.3 (±27.9) mU/l for the clonidine test and
14.8 (±11.1) mU/l for the sleep test. Mean values for the poor responders were 21.7
(±10.9), 35.5 (±29.8) and 19.8 (±9.9) mU/l respectively. These values were not statistically
different according to an unpaired t-test.
The percentage of patients whose response was correctly predicted by their height at the
start of treatment was 57%. This means that the patients who were smaller than -2.5 SDS
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and responded well to CH therapy, together with the patients who were taller than 2.5 SDS
and did not respond to GH, constituted 57% of all patients. The percentage of patients
whose response was correctly predicted by their deviation from the target height was 50%.
The corresponding value for the change in height in the year before therapy was 79%. The
change in TBW over six weeks divided by height^ correctly predicted the response of 89%
of the patients.
DISCUSSION
The present study evaluated the use of changes in body composition for the prediction of
the effect of GH therapy. Most children who responded well to GH therapy showed an
evident increase in TBW/height^, while the poor responders were indistinguishable from
controls. Total body water was measured as a function of height, in accordance with the
Body Mass Index (weight/height^), because children of different heights were compared.
This correction was justified by the strong correlation between TBW and height^ found in
the control group.
Two limits of normality were assumed. The upper limit for the change in TBW over six
weeks divided by height^ was established by taking the mean change in the control group
plus two times the standard deviation (0.93 I/W).
Figure 7c
Growth hormone concentrations found by the c/on/d/ne test (•,) s/eep test (o.) and arg/n/ne
test (A,), p/ofted aga/nst change /n SDS after one year.
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Because we applied age and sex matching, the two eldest prepubertal patients were
matched with already pubertal controls. However, we assumed that puberty has no
detectable effect on body composition within a period of six weeks.
Based on their response to GH therapy after one year, patients were divided into good and
poor responders (change in height above or below 0.7 SDS). Applying these two limits of
normality (0.7 SDS on the x-axis and 0.93 l/m^ on the y-axis) leads to four quadrants when
the change in SDS over one year is plotted against the change in TBW divided by height^.
As expected, all controls are situated in the lower left quadrant. The poor responders are
also found in this quadrant, meaning that no distinction can be made between controls and
poor responders. By contrast, 8 of the 10 good responders are in the upper right quadrant.
This graph thus shows sensitivity and specificity to be high (88% and 89%, respectively),
indicating that the use of changes in body composition is a reliable tool for the diagnosis of
GHD.
Patient selection in the present study was only based on anthropometric arguments and not
on endocrine testing, to prevent any bias from false-positive or false-negative biochemical
results. The present study could only be performed by including children with idiopathic short
stature, because of the need to include the whole range of expected responses to GH therapy,
poor as well as good. Parents were fully informed in advance of the possibility that the
therapy could have a disappointing effect. If after one year, the therapy did not prove to be
successful, the treatment was stopped. The endocrine tests that were nevertheless performed
showed that most children had two endocrine test results less than 20 mil/I (Figure 7c), but
a third test above 20 mU/l. Plotted against the change in height after one year, the results of
the endocrine tests were randomly distributed. If the start of GH treatment had been
dependent on these endocrine tests, meaning that all measured GH values had to be less than
20 mU/l, one good and one poor responder would have been treated.
In our group of patients, therefore, the use of endocrine tests did not lead to an accurate
prediction of the response to GH therapy, corroborating the conclusions of other reports in
the literature, which have questioned the reliability of endocrine tests. (19-24). By contrast,
the change in height in the year before therapy was found to predict the response of 79% of
the patients correctly, which comes close to the percentage of children whose response was
predicted correctly on the basis of the change in TBW over six weeks divided by height^, i.e.,
89%.
In conclusion, changes in body composition data proved to be valuable for the distinction
between good and poor responders to GH therapy. However, it should be realized that the
cut-off values used for growth response as well as change in body composition are more
or less arbitrary.
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Although recombinant growth hormone (CH) has been prescribed in GH-deficient patients
since 1985, it is still problematic to define the patients who will benefit from it. As the
current tests appear to be insufficient to predict the growth effect of growth hormone, a
better method is needed. The basic aim of the research reported on in this thesis was to
find an instrument that is able to predict the long-term effect of CH on growth by
measuring its short-term effect on physical activity and body composition.
There are several reasons why a good diagnostic tool to distinguish between good and poor
responders to CH therapy is needed. The most important reason is of course the proper
treatment of the patient, in terms of preventing unnecessary initiation of therapy as well as
interruption of the therapy as soon as it proves ineffective. However, GH therapy needs to
be sustained for at least six, but preferably twelve months before its anthropometric
effectiveness can be evaluated.
Current endocrine tests are not only poor predictors of the effect of CH therapy, especially
in partially CH-deficient patients, they are also unpleasant for children, because the drugs
which are used to provoke a GH response can have uncomfortable side effects.
High costs are another important factor creating a need for a better diagnostic tool. The
implementation of endocrine tests is expensive because it requires hospitalisation. In
addition, every test involves the analysis in the laboratory of many blood samples.
However, these are relatively insignificant compared to the costs of GH therapy itself, which
are about € 17,700 per patient per year, assuming a mean dosage of 1 mg per day. Because
of these high costs, the Dutch government has centralized the prescription of GH.
Based on the above-mentioned arguments it is of paramount importance that no subjects
should be treated without reliable prospects of enhanced growth. This would require high
test specificity, but high specificity usually implies that some subjects may not be treated,
even though they might have responded to therapy. On the other hand, including all
subjects who will respond to therapy would require a high sensitivity, but this implies that
some children who will not respond to CH therapy are also treated. It is therefore necessary
to decide which of the two aspects should predominate: treating all children that respond
to therapy or minimizing the negative aspects of treatment (the physical inconvenience of
daily injections, disappointment after high expectations of increased height, and high
costs).
The increasing numbers of parents and/or children presenting at the pediatrician with
problems of negative self-esteem because of short stature indicates the importance of
growth problems at the pediatric outpatient clinic. Height seems extremely important, as
being tall seems to be associated with higher income, self-esteem and social status (1, 2).
It is probably for this reason that parents are concerned when their child seems to have
growth problems. There is, however, no consensus about the negative physiologic effects
of short stature. It is believed that children with short stature, and especially children with
extremely short stature, will experience a range of problems in their daily lives. Although
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studies report that about 50-75% of short children are treated as if they were younger than
their actual age and are teased about their short stature (3, 4), most children generally
present as psychologically well adapted (2). By contrast, Stabler (5) concluded that many
children who are referred to paediatric endocrinologists have behavioral problems, some of
which ameliorate during treatment with GH. However, this effect may have been enhanced
by the study design, in that children with concurrent behavioral problems may be more
likely to be referred to the pediatric endocrinologists.
A key issue in the present study was to make a distinction between good and poor
responders to GH therapy. A change in height SDS after one year of 0.7 was taken as the
cut-off point, being the mean value found in a study by Ranke et al. (6), but also in an
analysis of growth data by the Dutch Growth Foundation (personal communication).
Although it is often claimed that all children tend to show a response during the first year
of GH therapy, this could not be confirmed in the present study, as there were children who
showed no change in height SDS in the first year of therapy. In addition, we assume that a
change of 0.7 height SDS is sufficient to identify these children as responders to GH
therapy.
Besides the influence on height, the effects of GH on metabolism are worth considering and
an important additional aspect for the patient. Children with Prader Willi syndrome, for
example, present with diminished growth, reduced lean body mass, obesity, hypotonia and
behavioral abnormalities. Apart from the increase in height, GH therapy in these children
causes an increase in lean body mass, physical strength and agility (7, 8) as well as
behavioral changes (8). This reduces some of the physical disabilities experienced by these
children, which might be just as important as, or even more important than, the height
increase. Awareness of this effect, not only in Prader Willy patients but also in other groups
(9-12), has led to the idea to use the metabolic consequences as predictors of the effect of
GH therapy on growth.
Metabolism can be translated into physical activity. However, before deviating levels of
physical activity in children receiving GH therapy could be established, normal values of
physical activity needed to be determined in healthy children. Chapter two shows that
physical activity levels (PAL) and activity related energy expenditure (AEE) increase with
age. This relation was not found when AEE was expressed per kg weight, indicating that
the increase in weight by age is probably a reason for the increase in PAL and AEE.
In addition to physical activity levels, accelerometry can be used to measure physical activity
patterns, assessing the percentage of time spent on activities of low- (sitting), moderate-
talking) and high-intensity (running) activities. Although the Tracmor2 device has been
shown to be a reliable instrument for the measurement of physical activity in adults (13), it
had not been used in children before, so we first validated it against data obtained using
the doubly labeled water (DLW) method. The high correlation (r=0.79) found between
Tracmor output and DLW data demonstrated that the Tracmor2 is a reliable tool to measure
physical activity in children (chapter 3).
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PAL values proved to be inversely related to the time spent on low-intensity activities and
directly related to the time spent on high-intensity activities in healthy, normally growing
children (chapter 4). This finding contrasted with findings in adults, whose physical activity
levels proved to be effectively increased by an increase in moderate-intensity activities (14)
probably because high-intensity activities are usually not sustained for long periods of time.
The specific activity patterns among children, which are characterized by short, intermittent
bouts of vigorous physical activity (15-18) were also reflected in the time children spent on
high-intensity activities. Children were found to spend more time on-high intensity
activities than adults, probably because their lower weight makes it easier for them to
perform high-intensity activities. However, even though children spent more time on high-
intensity activities, accelerometry revealed lower PAL values. Apart from the fact that it
takes children less energy to perform high-intensity activities because of their lower weight,
these low PAL values can probably be attributed to shorter total physical activity times, as
children sleep more than adults.
When comparing the activity patterns of GH-treated children with those of healthy,
normally growing controls (chapter 5), good responders to GH therapy were found to
spend less time on high-intensity activities before the start of treatment. After two weeks
of GH therapy, however, this difference had disappeared. Possible reasons for the decreased
level of physical activity might be impaired erythropoiesis and decreased plasma and total
blood volumes (19), factors that influence physical performance capacity (20). In GH-
deficient adults, such impaired erythropoiesis and decreased plasma and total blood
volumes have been proven to ameliorate during GH treatment (19, 21). Moller et al.
proved that plasma volume increases after as little as three weeks (22).
Poor responders to GH therapy did not differ from controls, and two weeks of therapy did
not influence their activity levels. GH probably had no effect on activity because the growth
retardation in this patient group was not based on GH deficiency. Endurance time, which
was measured before and during the first year of therapy, was not influenced by GH
therapy in this patient group either.
In the good responders, however, there was a significant increase in the length of time for
which the children were able to perform an endurance test on a treadmill. In addition to
the effects on erythropoiesis and blood volume, this improved endurance time was
probably caused by an increase in height (chapter 6).
Unfortunately, although changes in physical activity were measurable after a short period
of time in the good responders group, they were not predictive of the effect of GH therapy
on growth. The change in body composition as a result of GH administration proved to be
a more promising metabolic predictor of the growth effect. In adults, the under water
weighing (UWW) method is regarded as the "gold standard" for measuring body
composition. Applying this method to young children, however, is not without problems.
The UWW method is based on the measurement of body volume, and this body volume
as measured by UWW has to be corrected for lung volume, ideally by simultaneously
measuring the residual lung volume during submersion (23). This means that children have
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to be submersed in water with a mouthpiece in their mouth, which connects them to the
lung volume meter. This is technically difficult and frightening for young children, rendering
accurate measurements impossible. A problem in the measurement of body composition in
children is the need for age-dependent constants for the hydration of the fat-free mass (24,
25) since hydration of the fat-free mass changes with age. The under water weighing
method also depends on assumptions about a constant hydration of the fat-free mass.
Another disadvantage of the use of UWW is that most centres lack the equipment for this
method.
In the present study, body composition was measured using the deuterium dilution
technique, which is a good instrument to measure body composition in children (26). The
method is non-invasive and easily applicable, even in infants, because only small urine
samples are needed, which can be easily collected by placing cotton wools in the diaper.
The deuterium dilution method is based on the measurement of total body water (TBW).
To calculate the percentage of fat-free mass, TBW needs to be corrected for the hydration
of the fat free mass. This hydration factor is assumed to be 73% for adults, but this
constant factor cannot be used in children (25, 27). To exclude possible confounding by the
hydration of the fat-free mass, the present study used the actual total body water data.
The change in TBW/height^ was found to be a useful parameter to predict the effect of CH
therapy on growth (chapter 7). This method was capable of distinguishing between good
and poor responders, after as little as six weeks of treatment. Only two of the ten patients
who did respond to CH therapy did not show an increase in TBW/height^ differing from
controls. The time between the collection of the second urine sample and the ingestion of
the deuterium in these two patients may have been too long in the measurement before
the start of CH therapy. This causes an overestimation of the total body water and a smaller
difference after six weeks of therapy. A disadvantage of the deuterium method is that it
sometimes takes a long time before children are able to pass water so that a urine sample
can be collected. If this method is really to be used as the only diagnostic criterion for CHD,
the method should perhaps be performed in duplicate before as well as after therapy.
Because the method is non-invasive and relatively cheap, this would be the best way to
increase sensitivity and specificity.
Unlike all other models, this method can predict the GH response after as little as six weeks
of CH treatment, using only one effect parameter. Although we assessed a relatively small
number of patients, results for this small sample were very clear, indicating that it would be
useful to confirm the results in a larger sample. If this predictive model proves to be highly
specific for a large cohort as well, a trial period of six weeks can be recommended to select
those children who will benefit from the use of GH. This would mean that disappointment
after one year of ineffective therapy is avoided, as well as the physical discomfort of daily
injections over such a long period. In addition, the cost aspect is also important, as the cost
of one year of therapy would cover a six-week trial therapy for nine children.
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SUMMARY
Doctors are frequently confronted with children suspected of having a growth disorder. The
following criteria are used to assess whether they are really suffering from such a disorder:
• the child's height is more than 2.5 standard deviations below the average height of the
reference population to which the child belongs;
• the child's height is more than 1.3 standard deviations below the expected height based
on the parents' height (target height);
• a decrease in height of more than 0.25 standard deviations over one year.
If the child's growth meets one of these criteria, it is examined to detect any underlying
pathology. One of the possible causes is growth hormone (CH) deficiency. The main test
to establish such a deficiency is a growth hormone stimulation test, which in normal
persons shows an increase in serum growth hormone concentrations exceeding 20 mU/l.
If two separate tests result in an increase below this value, the child is basically eligible for
hormone therapy. However, the diagnostic value of these growth hormone tests has been
seriously criticized.
Since growth hormone is excreted in pulses, a serum concentration in one single sample is
unable to establish reduced secretion, which is why growth hormone stimulation tests are
used. The outcome of such tests, however, is subject to major intra- and inter-individual
variations depending on the agent used to stimulate hormone production. In addition, tests
implemented at different laboratories should be harmonized to exclude differences at
analytical level.
As with all medical interventions, the best proof of an effect is outcome. However, a reliable
anthropometric assessment of the effect of growth hormone therapy can only be made
after at least 6, but preferably 12 months, of treatment. And since growth hormone
treatment involves daily injection and is a costly form of treatment, it would be valuable to
be able to assess its effectiveness sooner.
In addition to its effect on growth, growth hormone also affects metabolism, an effect that
starts shortly after the treatment is initiated. The present study was undertaken to evaluate
whether changes in metabolism, expressed as energy expenditure and body composition,
could be used to predict the effects of growth hormone on growth.
The main component of the total daily energy expenditure (TDEE) is the energy needed to
maintain all vital body functions, the basal metabolic rate. The amount of energy invested
in physical activity is the most variable component of the TDEE. The gold standard to
measure TDEE is the doubly labeled water method. When the basal metabolic rate is
measured in addition to TDEE, the amount of energy invested in physical activities,
expressed as PAL (physical activity level) and AEE (activity related energy expenditure) can
be established.
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An attempt was made to establish normal values for the relation between activity levels and
age by analyzing the results of 17 studies using doubly labeled water. The amount of
energy invested in physical activities, expressed as PAL and AEE was found to rise with age.
Since no relation was found between age and the ratio of AEE to body weight, the rise in
the amount of energy spent on physical activities is probably caused by the rise in body
weight.
The children's activity patterns were measured with the help of the Tracmor2. The Tracmor2
is an accelerometer, which records the occurrence and intensity of movements. Activities
were categorized as low-intensity (sitting), moderate-intensity (walking) or high-intensity
(running). The study showed that children spent a larger percentage of their time on high-
intensity activities, as their lower body weight means such activities require less energy
expenditure from them than from adults. PAL values were found to be related to the
percentage of time spent on low- and high-intensity activities.
Activity patterns of children with normal growth were compared with those of children
undergoing a growth hormone therapy. After a year of growth hormone therapy, the
patients were subdivided into good responders (change in height > 0.7 standard deviation
score (SDS)) and poor responders (change in height < 0.7 SDS). Before the start of the
growth hormone therapy, good responders spent a smaller percentage of their active time
on high-intensity activities than controls with a normal growth. This difference had
disappeared after two weeks of growth hormone therapy. The control group and the group
of poor responders showed no such change in activity pattern. In addition to physical
activity, we also measured the children's endurance time on a treadmill test. Good
responders showed improved endurance time after a year of growth hormone treatment,
while poor responders and controls showed no such change in endurance time. These
effects on activity patterns could, however, not be used to predict the children's response
to growth hormone therapy.
By contrast, changes in body composition were found to have a good predictive value for
the effect of growth hormone therapy on the children's growth. Body composition was
measured using the deuterium dilution method, and expressed as total body water (TBW).
Changes in TBW were divided by the square of the child's height, comparable to what is
used in the body mass index (BMI = weight/height^), in order to correct for height
differences. Among good responders, changes in TBW/height^ during the first six weeks of
growth hormone treatment were more than twice the standard deviation range of the
controls. By contrast, poor responders could not be distinguished from controls. We
concluded that changes in TBW/height^ after as little as six weeks predict the effect of
growth hormone therapy on the child's growth.
The value of the present study is that six weeks of trial therapy are enough to reliably
predict the long-term effect of growth hormone treatment, using a cheap test, which
represents no great burden to the patient. The short trial period not only means a greatly
reduced burden to the child, but can also have a considerable cost-saving effect.
107
S«nenvatting I
SAMENVATTING
In de geneeskunde worden dikwijls kinderen gepresenteerd met een vermeende
groeistoornis. Om te beoordelen of daarvan ook werkelijk sprake is worden de volgende
criteria gehanteerd:
• de lengte van het kind ligt meer dan 2.5 standaard deviaties onder de gemiddelde
lengte van de referentiepopulatie waartoe het kind behoort;
• de lengte van het kind ligt meer dan 1.3 standaard deviaties onder de verwachte lengte
op basis van de ouderlengte (target height);
• de lengteafbuiging in een jaar is groter dan 0.25 standaard deviaties.
Indien de lengtegroei van een kind aan een van deze criteria voldoet, wordt onderzoek
verricht naar onderliggende pathologic Een van de oorzaken kan groeihormoon(GH)-
deficientie zijn. De belangrijkste test om een dergelijke deficientie aan te tonen is een GH-
stimulatietest, waarbij een stijging van de serum GH-concentratie boven 20 mU/l als
normaal wordt beschouwd. Bij een geringere stijging, tijdens tenminste twee testen, komt
het kind in principe in aanmerking voor een groeihormoon-behandeling. Echter, de
diagnostische waarde van groeihormoontesten is aan veel kritiek onderhevig.
Omdat GH pulsatiel wordt uitgescheiden kan een enkelvoudige bepaling van de
serumconcentratie niet gebruikt worden om een verminderde groeihormoonsecretie vast te
stellen. Daarom wordt gebruik gemaakt van groeihormoon-stimulatietesten, waarbij het
resultaat echter grote intra- en interindividuele verschillen kan vertonen op basis van het
gebruikte agens als stimulator. Daarnaast is harmonisatie van laboratoria noodzakelijk om
verschillen in uitslag op analytisch niveau uit te sluiten.
Zoals geldt voor iedere medische interventie is het resultaat het beste bewijs voor een
effect. Anthropometrisch is het effect van groeihormoon pas betrouwbaar vast te stellen na
een behandeling van tenminste 6 maar bij voorkeur 12 maanden. Omdat een
groeihormoonbehandeling dagelijkse injecties met zieh meebrengt en een dure
behandeling is, is het wenselijk de effectiviteit al op kortere termijn vast te kunnen stellen.
Naast een effect op de groei heeft groeihormoon, al snel na de start van de behandeling,
een effect op het metabolisme. De huidige studie is uitgevoerd om te onderzoeken of
veranderingen in metabolisme, weerspiegeld in energiegebruik en lichaamssamenstelling,
een voorspellingsmaat zijn voor het effect van groeihormoon op de groei.
De grootste component van het totale energiegebruik (TDEE= total daily energy
expenditure), is de hoeveelheid energie die in rust wordt gebruikt, ook wel het basaal
metabolisme genoemd. De hoeveelheid energie die aan fysieke activiteit wordt besteed is
de meest variable component van het TDEE. De gouden standaard om het TDEE te meten
is de tweevoudig gemerkt water methode. Wanneer naast het TDEE het basaal
metabolisme wordt gemeten, kan de energie die wordt besteed aan fysieke activiteit
uitgedrukt als PAL (physical activity level = fysieke activiteiten niveau) en AEE (activity
related energy expenditure = activiteit gerelateerde energie) worden bepaald.
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Teneinde te komen tot normaalwaarden van activiteit in relatie tot leeftijd werden de
gegevens van 17 studies, waarin de tweevoudig gemerkt water methode was gebruikt,
geanalyseerd. De hoeveelheid energie besteed aan fysieke activiteit, uitgedrukt als PAL en
AEE, bleek te stijgen met de leeftijd. Omdat er geen relatie werd gevonden tussen leeftijd
en AEE/gewicht wordt de stijging in de hoeveelheid energie die aan activiteit wordt
besteed, waarschijnlijk veroorzaakt door een stijging in gewicht.
Activiteitenpatronen van kinderen werden gemeten met de Tracmor2. Tracmor2 is een
versnellingsopnemer die het voorkomen en de intensiteit van beweging registreert.
Activiteiten werden onderverdeeld in categorieen van läge (zitten), middelmatige
(wandelen) en hoge (rennen) intensiteit. Deze studie toonde aan dat kinderen relatief meer
tijd besteden aan activiteiten met een hoge intensiteit in vergelijking met volwassenen,
waarschijnlijk omdat hun dit minder energie kost vanwege hun lagere lichaamsgewicht.
Ook bleken PAL-waarden gerelateerd aan het percentage van de tijd dat werd besteed aan
läge- en hoge- intensiteit activiteiten.
Het activiteitenpatroon van normaal groeiende kinderen werd vergeleken met dat van
kinderen die een GH-behandeling kregen. Na een jaar GH-behandeling werden de
kinderen onderverdeeld in kinderen die goed (verandering in lengte > 0.7 standaardeviatie
score (SDS)) en matig (verandering in lengte < 0.7 SDS) hadden gereageerd op de GH-
behandeling. Voor aanvang van de GH-behandeling besteedden de kinderen die goed
reageerden, relatief minder van de tijd dat ze actief waren aan hoge-intensiteit activiteiten
dan normaal groeiende controles. Na 2 weken behandeling met GH was dit verschil
verdwenen. In de controlegroep en de groep met kinderen die matig reageerden, werd
geen verandering in activiteit gevonden. Naast de fysieke activiteit werd het
uithoudingsvermogen van de kinderen gemeten. De kinderen die goed reageerden, hielden
een inspanningstest langer vol na een jaar behandeling. In de groep kinderen die een
matige reactie lieten zien op de GH-behandeling en de controlegroep werd geen
verandering gevonden in de tijd dat ze een inspanningstest vol konden houden. Ondanks
dat deze effecten op activiteit werden gevonden, konden deze effecten niet worden
gebruikt om een reactie van GH op de groei te voorspellen.
Veranderingen in lichaamssamenstelling bleken een sterk voorspellende waarde te hebben
voor het effect van GH op de groei. De lichaamssamenstelling werd gemeten met behulp
van de deuterium-verdunningsmethode en uitgedrukt in totaal lichaamswater (TBW=total
body water). De veranderingen in TBW werden gedeeld door lengte^, vergelijkbaar met de
body mass index (BMI=gewicht/lengte^), om te corrigeren voor verschillen in lengte.
Veranderingen in TBW/Iengte^ tijdens de eerste 6 weken van de GH-behandeling, waren
in de groep met kinderen die goed reageerden op de behandeling groter dan 2 keer de
standaarddeviatie-grens van de controles. De kinderen die matig reageerden, konden
echter niet worden onderscheiden van de controles. Daarom werd geconcludeerd dat al na
6 weken veranderingen in TBW/lengte^ een voorspellende waarde hebben op het effect
van GH op de groei.
Het belang van deze studie is dat met behulp van een proefbehandeling van 6 weken op
betrouwbare wijze, met behulp van een niet-belastende en goedkope methode, een
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uitspraak gedaan kan worden over het lange termijn effect van groeihormoon op de groei.
Door de korte duur van de proefbehandeling betekent dit niet alleen een enorme
lastenverlichting voor het kind, maar is dit ook economisch zeer aantrekkelijk.
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